1
|
Kumar N, Sharma AK, Guleria M, Shelar SB, Chakraborty A, Rakshit S, Kolay S, Satpati D, Das T. Nuclear Localization Signal Enhances the Targeting and Therapeutic Efficacy of a Porphyrin-Based Molecular Cargo: A Systemic In Vitro and Ex Vivo Evaluation. Mol Pharm 2024; 21:2351-2364. [PMID: 38477252 DOI: 10.1021/acs.molpharmaceut.3c01152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/14/2024]
Abstract
The objective of the present work was to evaluate the potential of a nuclear localization signal (NLS) toward facilitating intracellular delivery and enhancement in the therapeutic efficacy of the molecular cargo. Toward this, an in-house synthesized porphyrin derivative, namely, 5-carboxymethyelene-oxyphenyl-10,15,20-tris(4-methoxyphenyl) porphyrin (UTriMA), was utilized for conjugation with the NLS sequence [PKKKRKV]. The three compounds synthesized during the course of the present work, namely DOTA-Lys-NLS, DOTA-UTriMA-Lys-NLS, and DOTA-Lys-UTriMA, were evaluated for cellular toxicity in cancer cell lines (HT1080), wherein all exhibited minimal dark toxicity. However, during photocytotoxicity studies with DOTA-Lys-UTriMA and DOTA-UTriMA-Lys-NLS conjugates in the same cell line, the latter exhibited significantly higher light-dependent toxicity compared to the former. Furthermore, the photocytotoxicity for DOTA-UTriMA-Lys-NLS in a healthy cell line (WI26VA4) was found to be significantly lower than that observed in the cancer cells. Fluorescence cell imaging studies carried out in HT1080 cancer cells revealed intracellular accumulation for the NLS-conjugated porphyrin (DOTA-UTriMA-Lys-NLS), whereas unconjugated porphyrin (DOTA-Lys-UTriMA) failed to do so. To evaluate the radiotherapeutic effects of the synthesized conjugates, all three compounds were radiolabeled with 177Lu, a well-known therapeutic radionuclide with high radiochemical purity (>95%). During in vitro studies, the [177Lu]Lu-DOTA-UTriMA-Lys-NLS complex exhibited the highest cell binding as well as internalization among the three radiolabeled complexes. Biological distribution studies for the radiolabeled compounds were performed in a fibrosarcoma-bearing small animal model, wherein significantly higher accumulation and prolonged retention of [177Lu]Lu-DOTA-UTriMA-Lys-NLS (9.32 ± 1.27% IA/g at 24 h p.i.) in the tumorous lesion compared to [177Lu]Lu-UTriMA-Lys-DOTA (2.3 ± 0.13% IA/g at 24 h p.i.) and [177Lu]Lu-DOTA-Lys-NLS complexes (0.26 ± 0.17% IA/g at 24 h p.i.) were observed. The results of the biodistribution studies were further corroborated by recording serial SPECT-CT images of fibrosarcoma-bearing Swiss mice administered with [177Lu]Lu-DOTA-UTriMA-Lys-NLS at different time points. Tumor regression studies performed with [177Lu]Lu-DOTA-UTriMA-Lys-NLS in the same animal model with two different doses [250 μCi (9.25 MBq) and 500 μCi (18.5 MBq)] resulted in a significant reduction in tumor mass in the treated group of animals. The above results revealed a definite enhancement in the targeting ability of molecular cargo upon conjugation with NLS and hence indicated that this strategy may be helpful for the preparation of drug-NLS conjugates as multimodal agents.
Collapse
Affiliation(s)
- Naveen Kumar
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400085, India
- Homi Bhabha National Institute, Anushaktinagar, Mumbai 400094, India
| | - Amit K Sharma
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400085, India
- Homi Bhabha National Institute, Anushaktinagar, Mumbai 400094, India
| | - Mohini Guleria
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400085, India
- Homi Bhabha National Institute, Anushaktinagar, Mumbai 400094, India
| | - Sandeep B Shelar
- Chemistry Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400085, India
| | - Avik Chakraborty
- Radiation Medicine Centre, Bhabha Atomic Research Centre, Parel, Mumbai 400012, India
| | - Sutapa Rakshit
- Radiation Medicine Centre, Bhabha Atomic Research Centre, Parel, Mumbai 400012, India
| | - Soumi Kolay
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400085, India
| | - Drishty Satpati
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400085, India
- Homi Bhabha National Institute, Anushaktinagar, Mumbai 400094, India
| | - Tapas Das
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400085, India
- Homi Bhabha National Institute, Anushaktinagar, Mumbai 400094, India
| |
Collapse
|
2
|
Patra S, Dey J, Kar S, Chakraborty A. Delivery of Chlorambucil to the Brain Using Surface Modified Solid Lipid Nanoparticles. ACS Appl Bio Mater 2024. [PMID: 38700026 DOI: 10.1021/acsabm.4c00326] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/05/2024]
Abstract
The delivery of drugs to the brain in the therapy of diseases of the central nervous system (CNS) remains a continuing challenge because of the lack of delivery systems that can cross the blood-brain barrier (BBB). Therefore, there is a need to develop an innovative delivery method for the treatment of CNS diseases. Thus, we have investigated the interaction of γ-aminobutyric acid (GABA) and S-(-)-γ-amino-α-hydroxybutyric acid (GAHBA) with the GABA receptor by performing a docking study. Both GABA and GAHBA show comparable binding affinities toward the receptor. In this study, we developed surface-modified solid lipid nanoparticles (SLNs) using GAHBA-derived lipids that can cross the BBB. CLB-loaded SLNs were characterized by a number of methods including differential scanning calorimetry, dynamic light scattering, UV-vis spectroscopy, and transmission electron microscopy. The blank and CLB-loaded SLN suspensions were found to exhibit good storage stability. Also, the SLNs showed a higher encapsulation efficiency for CLB drugs. In vitro release kinetics of CLB at physiological temperature was also investigated. The results of the in vitro cell cytotoxicity assay and flow cytometry studies in the human glioma U87MG cell line and human prostate cancer PC3 cell line suggested a higher efficacy of the GAHBA-modified CLB-loaded SLNs in U87MG cells. The transcription level of GABA receptor expression in the target organ and cell line was analyzed by a reverse transcription polymerase chain reaction study. The in vivo biodistribution and brain uptake in C57BL6 mice and SPECT/CT imaging in Wistar rats investigated using 99mTc-labeled SLN and autoradiography suggest that the SLNs have an increasing brain uptake. We have demonstrated the delivery of the anticancer drug chlorambucil (CLB) to glioma.
Collapse
Affiliation(s)
- Swagata Patra
- Department of Chemistry, Indian Institute of Technology Kharagpur, Kharagpur 721302, India
| | - Joykrishna Dey
- Department of Chemistry, Indian Institute of Technology Kharagpur, Kharagpur 721302, India
| | - Somnath Kar
- Radiation Medicine Centre, Bhabha Atomic Research Centre, Parel, Mumbai 400012, India
| | - Avik Chakraborty
- Radiation Medicine Centre, Bhabha Atomic Research Centre, Parel, Mumbai 400012, India
| |
Collapse
|
3
|
Ghosh S, Patra S, Younis MH, Chakraborty A, Guleria A, Gupta SK, Singh K, Rakhshit S, Chakraborty S, Cai W, Chakravarty R. Brachytherapy at the nanoscale with protein functionalized and intrinsically radiolabeled [ 169Yb]Yb 2O 3 nanoseeds. Eur J Nucl Med Mol Imaging 2024; 51:1558-1573. [PMID: 38270686 DOI: 10.1007/s00259-024-06612-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2023] [Accepted: 01/09/2024] [Indexed: 01/26/2024]
Abstract
PURPOSE Classical brachytherapy of solid malignant tumors is an invasive procedure which often results in an uneven dose distribution, while requiring surgical removal of sealed radioactive seed sources after a certain period of time. To circumvent these issues, we report the synthesis of intrinsically radiolabeled and gum Arabic glycoprotein functionalized [169Yb]Yb2O3 nanoseeds as a novel nanoscale brachytherapy agent, which could directly be administered via intratumoral injection for tumor therapy. METHODS 169Yb (T½ = 32 days) was produced by neutron irradiation of enriched (15.2% in 168Yb) Yb2O3 target in a nuclear reactor, radiochemically converted to [169Yb]YbCl3 and used for nanoparticle (NP) synthesis. Intrinsically radiolabeled NP were synthesized by controlled hydrolysis of Yb3+ ions in gum Arabic glycoprotein medium. In vivo SPECT/CT imaging, autoradiography, and biodistribution studies were performed after intratumoral injection of radiolabeled NP in B16F10 tumor bearing C57BL/6 mice. Systematic tumor regression studies and histopathological analyses were performed to demonstrate therapeutic efficacy in the same mice model. RESULTS The nanoformulation was a clear solution having high colloidal and radiochemical stability. Uniform distribution and retention of the radiolabeled nanoformulation in the tumor mass were observed via SPECT/CT imaging and autoradiography studies. In a tumor regression study, tumor growth was significantly arrested with different doses of radiolabeled NP compared to the control and the best treatment effect was observed with ~ 27.8 MBq dose. In histopathological analysis, loss of mitotic cells was apparent in tumor tissue of treated groups, whereas no significant damage in kidney, lungs, and liver tissue morphology was observed. CONCLUSIONS These results hold promise for nanoscale brachytherapy to become a clinically practical treatment modality for unresectable solid cancers.
Collapse
Affiliation(s)
- Sanchita Ghosh
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai, 400085, India
- Homi Bhabha National Institute, Anushaktinagar, Mumbai, 400094, India
| | - Sourav Patra
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai, 400085, India
- Homi Bhabha National Institute, Anushaktinagar, Mumbai, 400094, India
| | - Muhsin H Younis
- Departments of Radiology and Medical Physics, University of Wisconsin-Madison, Madison, USA
| | - Avik Chakraborty
- Homi Bhabha National Institute, Anushaktinagar, Mumbai, 400094, India
- Radiation Medicine Centre, Bhabha Atomic Research Centre, Parel, Mumbai, 400012, India
| | - Apurav Guleria
- Homi Bhabha National Institute, Anushaktinagar, Mumbai, 400094, India
- Radiation and Photochemistry Division, Bhabha Atomic Research Centre, Trombay, Mumbai, 400085, India
| | - Santosh K Gupta
- Homi Bhabha National Institute, Anushaktinagar, Mumbai, 400094, India
- Radiochemistry Division, Bhabha Atomic Research Centre, Trombay, Mumbai, 400085, India
| | - Khajan Singh
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai, 400085, India
| | - Sutapa Rakhshit
- Radiation Medicine Centre, Bhabha Atomic Research Centre, Parel, Mumbai, 400012, India
| | - Sudipta Chakraborty
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai, 400085, India
- Homi Bhabha National Institute, Anushaktinagar, Mumbai, 400094, India
| | - Weibo Cai
- Departments of Radiology and Medical Physics, University of Wisconsin-Madison, Madison, USA.
| | - Rubel Chakravarty
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai, 400085, India.
- Homi Bhabha National Institute, Anushaktinagar, Mumbai, 400094, India.
| |
Collapse
|
4
|
Affiliation(s)
- Debanjan Bhattacharjee
- Dept. of Psychiatry, ESI-PGIMSR, ESIC Medical College and ESIC Hospital & ODC (EZ), Joka, West Bengal, India
| | - Avik Chakraborty
- Dept. of Psychiatry, ESI-PGIMSR, ESIC Medical College and ESIC Hospital & ODC (EZ), Joka, West Bengal, India
| |
Collapse
|
5
|
Balhara A, Gupta SK, Sudarshan K, Patra S, Chakraborty A, Chakraborty S. ZnAl 2O 4:Er 3+ Upconversion Nanophosphor for SPECT Imaging and Luminescence Modulation via Defect Engineering. ACS Appl Bio Mater 2024; 7:2354-2366. [PMID: 38481091 DOI: 10.1021/acsabm.4c00036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/16/2024]
Abstract
This work reports an "all-in-one" theranostic upconversion luminescence (UCL) system having potential for both diagnostic and therapeutic applications. Despite considerable efforts in designing upconversion nanoparticles (UCNPs) for multimodal imaging and tumor therapy, there are few reports investigating dual modality SPECT/optical imaging for theranostics. Especially, research focusing on in vivo biodistribution studies of intrinsically radiolabeled UCNPs after intravenous injection is of utmost importance for the potential clinical translation of such formulations. Here, we utilized the gamma emission from 169Er and 171Er radionuclides for the demonstration of radiolabeled ZnAl2O4:171/169Er3+ as a potent agent for dual-modality SPECT/optical imaging. No uptake of radio nanoformulation was detected in the skeleton after 4 h of administration, which evidenced the robust integrity of ZnAl2O4:169/171Er3+. Combining the therapeutics using the emission of β- particulates from 169Er and 171Er will be promising for the radio-theranostic application of the synthesized ZnAl2O4:169/171Er3+ nanoformulation. Cell toxicity studies of ZnAl2O4:1%Er3+ nanoparticles were examined by an MTT assay in B16F10 mouse melanoma cell lines, which demonstrated good biocompatibility. In addition, we explored the mechanism of UCL modulation via defect engineering by Bi3+ codoping in the ZnAl2O4:Er3+ upconversion nanophosphor. The UCL color tuning was successfully achieved from the red to the green region as a function of Bi3+ codoping concentrations. Further, we tried to establish a correlation of UCL tuning with the intrinsic oxygen and cation vacancy defects as a function of Bi3+ codoping concentrations with the help of electron paramagnetic resonance (EPR) and positron annihilation lifetime spectroscopy (PALS) studies. This study contributes to building a bridge between nature of defects and UC luminescence that is crucial for the design of advanced UCNPs for theranostics.
Collapse
Affiliation(s)
- Annu Balhara
- Homi Bhabha National Institute, Anushaktinagar, Mumbai 400094, India
- Radiochemistry Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400085, India
| | - Santosh K Gupta
- Homi Bhabha National Institute, Anushaktinagar, Mumbai 400094, India
- Radiochemistry Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400085, India
| | - Kathi Sudarshan
- Homi Bhabha National Institute, Anushaktinagar, Mumbai 400094, India
- Radiochemistry Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400085, India
| | - Sourav Patra
- Homi Bhabha National Institute, Anushaktinagar, Mumbai 400094, India
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400085, India
| | - Avik Chakraborty
- Homi Bhabha National Institute, Anushaktinagar, Mumbai 400094, India
- Radiation Medicine Centre (Medical), Bhabha Atomic Research Centre, Parel, Mumbai 400012, India
| | - Sudipta Chakraborty
- Homi Bhabha National Institute, Anushaktinagar, Mumbai 400094, India
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400085, India
| |
Collapse
|
6
|
Chaudhury R, Chakraborty A, Rahaman F, Sarkar T, Dey S, Das M. Mycorrhization in trees: ecology, physiology, emerging technologies and beyond. Plant Biol (Stuttg) 2024; 26:145-156. [PMID: 38194349 DOI: 10.1111/plb.13613] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/02/2023] [Accepted: 11/30/2023] [Indexed: 01/10/2024]
Abstract
Mycorrhization has been an integral part of plants since colonization by the early land plants. Over decades, substantial research has highlighted its potential role in improving nutritional efficiency and growth, development and survival of crop plants. However, the focus of this review is trees. Evidence have been provided to explain ecological and physiological significance of mycorrhization in trees. Advances in recent technologies (e.g., metagenomics, artificial intelligence, machine learning, agricultural drones) may open new windows to apply this knowledge in promoting tree growth in forest ecosystems. Dual mycorrhization relationships in trees and even triple relationships among trees, mycorrhizal fungi and bacteria offer an interesting physiological system to understand how plants interact with other organisms for better survival. Besides, studies indicate additional roles of mycorrhization in learning, memorizing and communication between host trees through a common mycorrhizal network (CMN). Recent observations in trees suggest that mycorrhization may even promote tolerance to multiple abiotic (e.g., drought, salt, heavy metal stress) and biotic (e.g. fungi) stresses. Due to the extent of physiological reliance, local adaptation of trees is heavily impacted by the mycorrhizal community. This knowledge opens the possibility of a non-GMO avenue to promote tree growth and development. Indeed, mycorrhization could impact growth of trees in nurserys and subsequent survival of the inoculated trees in field conditions. Future studies might integrate hyperspectral imaging and drone technologies to identify tree communities that are deficient in nitrogen and spray mycorrhizal spore formulations on them.
Collapse
Affiliation(s)
- R Chaudhury
- Department of Life Sciences, Presidency University, Kolkata, India
| | - A Chakraborty
- Department of Life Sciences, Presidency University, Kolkata, India
| | - F Rahaman
- Department of Life Sciences, Presidency University, Kolkata, India
| | - T Sarkar
- Department of Life Sciences, Presidency University, Kolkata, India
| | - S Dey
- Department of Life Sciences, Presidency University, Kolkata, India
| | - M Das
- Department of Life Sciences, Presidency University, Kolkata, India
| |
Collapse
|
7
|
Chakraborty A, Mitra A, Sahu S, Tawate M, Lad S, Kamaldeep, Rakshit S, Upadhye Bannore T, Gaikwad S, Dhotre G, Ray MK, Damle A, Basu S, Banerjee S. Intricacies in the Preparation of Patient Doses of [ 177Lu]Lu-Rituximab and [ 177Lu]Lu-Trastuzumab Using Low Specific Activity [ 177Lu]LuCl 3: Methodological Aspects. Mol Imaging Biol 2024; 26:61-80. [PMID: 37673943 DOI: 10.1007/s11307-023-01846-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2022] [Revised: 08/04/2023] [Accepted: 08/07/2023] [Indexed: 09/08/2023]
Abstract
The development of humanized monoclonal antibodies (MAbs) with Lutetium-177 ([177Lu]Lu3+) has brought a paradigm shift in the arena of targeted therapy of various cancers. [177Lu]Lu-DOTA-Rituximab and [177Lu]Lu-DOTA-Trastuzumab have gained prominence due to their improved therapeutic efficacy in the treatment of lymphoma and breast cancer. The clinical dose formulation of these radiolabeled MAbs, using low specific activity [177Lu]LuCl3, requires extensive optimization of the radiolabeling protocol. The present study merits the development of a single protocol which has been optimized for conjugation of Rituximab and Trastuzumab with p-NCS-benzyl-DOTA and further radiolabeling these immunoconjugates (ICs) with low specific activity [177Lu]LuCl3. Herein, we report a consistent and reproducible protocol for clinical dose formulations of [177Lu]Lu-DOTA-Rituximab and [177Lu]Lu-DOTA-Trastuzumab (~9.25 GBq each, equivalent to ~2 patient doses) with radiochemical yield (RCY) between 84 and 86% and radiochemical purities (RCP) >99%. The in vitro stabilities of both these radioimmunoconjugates (RICs) were retained up to 120 h post-radiolabeling, upon storage with L-ascorbic acid as stabilizer (concentration: ~ 220-240 μg/37MBq) at -20 °C. The ready-to-use formulation of clinical doses[177Lu]Lu-DOTA-Rituximab and [177Lu]Lu-DOTA-Trastuzumab has been successfully achieved by employing a single optimized protocol. While [177Lu]Lu-DOTA-Rituximab has exhibited a high degree of localization in retroperitoneal nodal mass of refractory lymphoma patient, high uptake of [177Lu]Lu-DOTA-Trastuzumab has been observed in metastatic breast carcinoma patient with multiple skeletal metastases.
Collapse
Affiliation(s)
- Avik Chakraborty
- Radiation Medicine Centre, Bhabha Atomic Research Centre, Parel, Mumbai, India
- Homi Bhabha National Institute, Mumbai, India
| | - Arpit Mitra
- Radiopharmaceuticals Laboratory, Board of Radiation and Isotope Technology, Vashi, Navi Mumbai, India
| | - Sudeep Sahu
- Radiation Medicine Centre, Bhabha Atomic Research Centre, Parel, Mumbai, India
| | - Megha Tawate
- Radiation Medicine Centre, Bhabha Atomic Research Centre, Parel, Mumbai, India
- Homi Bhabha National Institute, Mumbai, India
| | - Sangita Lad
- Radiation Medicine Centre, Bhabha Atomic Research Centre, Parel, Mumbai, India
| | - Kamaldeep
- Homi Bhabha National Institute, Mumbai, India
- Health Physics Division, Bhabha Atomic Research Centre, Trombay, Mumbai, India
| | - Sutapa Rakshit
- Radiation Medicine Centre, Bhabha Atomic Research Centre, Parel, Mumbai, India
| | | | - Sujay Gaikwad
- Radiation Medicine Centre, Bhabha Atomic Research Centre, Parel, Mumbai, India
| | - Geetanjali Dhotre
- Department of Chemical Sciences, Tata Institute of Fundamental Research, Mumbai, India
| | - Mukti Kanta Ray
- Radiation Medicine Centre, Bhabha Atomic Research Centre, Parel, Mumbai, India
- Homi Bhabha National Institute, Mumbai, India
| | - Archana Damle
- Radiation Medicine Centre, Bhabha Atomic Research Centre, Parel, Mumbai, India
- Homi Bhabha National Institute, Mumbai, India
| | - Sandip Basu
- Radiation Medicine Centre, Bhabha Atomic Research Centre, Parel, Mumbai, India
- Homi Bhabha National Institute, Mumbai, India
| | - Sharmila Banerjee
- Homi Bhabha National Institute, Mumbai, India.
- Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Kharghar, Navi Mumbai, 410 210, India.
| |
Collapse
|
8
|
Sharma AK, Sharma R, Das A, Chakraborty A, Rakshit S, Sarma HD, Mukherjee A, Das T, Satpati D. Synthesis and 177Lu Labeling of the First Retro Analog of the HER2-Targeting A9 Peptide: A Superior Variant. Bioconjug Chem 2023; 34:1576-1584. [PMID: 37379455 DOI: 10.1021/acs.bioconjchem.3c00265] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/30/2023]
Abstract
The retro analog of the HER2-targeting A9 peptide was synthesized by coupling amino acids in a reverse fashion and switching the N-terminal in the original sequence of the L-A9 peptide (QDVNTAVAW) to the C-terminal in rL-A9 (WAVATNVDQ). Modification in the backbone resulted in higher conformational stability of the retro peptide as evident from CD spectra. Molecular docking analysis revealed a higher HER2 binding affinity of [177Lu]Lu-DOTA-rL-A9 than the original radiopeptide [177Lu]Lu-DOTA-L-A9. Enormously enhanced metabolic stability of the retro analog led to significant elevation in tumor uptake and retention. SPECT imaging studies corroborated biodistribution results demonstrating a remarkably higher tumor signal for [177Lu]Lu-DOTA-rL-A9. The presently studied retro probe has promising efficiency for clinical screening.
Collapse
Affiliation(s)
- Amit Kumar Sharma
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, Maharashtra 400085, India
- Homi Bhabha National Institute, Mumbai 400094, India
| | - Rohit Sharma
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, Maharashtra 400085, India
- Homi Bhabha National Institute, Mumbai 400094, India
| | - Amit Das
- Radiation Biology and Health Sciences Division, Bhabha Atomic Research Centre, Mumbai, Maharashtra 400085, India
- Homi Bhabha National Institute, Mumbai 400094, India
| | - Avik Chakraborty
- Radiation Medicine Centre, Bhabha Atomic Research Centre, Mumbai, Maharashtra 400012, India
- Homi Bhabha National Institute, Mumbai 400094, India
| | - Sutapa Rakshit
- Radiation Medicine Centre, Bhabha Atomic Research Centre, Mumbai, Maharashtra 400012, India
| | - Haladhar Dev Sarma
- Radiation Biology and Health Sciences Division, Bhabha Atomic Research Centre, Mumbai, Maharashtra 400085, India
| | - Archana Mukherjee
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, Maharashtra 400085, India
- Homi Bhabha National Institute, Mumbai 400094, India
| | - Tapas Das
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, Maharashtra 400085, India
- Homi Bhabha National Institute, Mumbai 400094, India
| | - Drishty Satpati
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, Maharashtra 400085, India
- Homi Bhabha National Institute, Mumbai 400094, India
| |
Collapse
|
9
|
Ghosh R, León-Ruiz M, Dubey S, Chakraborty A, Benito-León J. Higher-level gait disorder as a presenting manifestation of progressive supranuclear palsy: a video case report. Rev Neurol 2023; 77:101-104. [PMID: 37489858 PMCID: PMC10662190 DOI: 10.33588/rn.7704.2022393] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2023] [Indexed: 07/26/2023]
Abstract
INTRODUCTION Frontal gait disorder/gait apraxia is a higher-order motor deficit with various causes, characterized by difficulties with gait initiation, such as freezing or ignition failure. We aimed to report a patient who presented with progressive higher-level gait disorder and fall episodes as the initial manifestations of progressive supranuclear palsy (PSP). Patient data were obtained from medical records from the Department of General Medicine, Burdwan Medical College and Hospital (Burdwan, West Bengal, India). CASE REPORT A 58-year-old previously healthy woman presented with a gait disorder and fall episodes. Detailed neurological examination highlighted characteristic facial appearance (wide-eyed staring, furrowing of the forehead with a frowning expression, and fixed expression of the lower face). She was hypokinetic-rigid with symmetrical signs and predominant axial rigidity with retrocolic trunk and neck posture. Gait examination revealed a higher-level gait pattern characterized by an exhibition of profound start hesitation requiring assistance from nearby objects/persons. Once walking was underway, steps became relatively better, but ineffective gait re-emerged when she attempted turning. She had short strides, freezing, broad stance base, disequilibrium, slow leg movement, shuffling, and loss of normal fluidity of trunk and limbs. Postural reflexes were impaired. Brain magnetic resonance imaging revealed atrophy of the midbrain, dilated aqueduct of Sylvius and third ventricle, atrophy of frontal lobes and typical hummingbird sign. Diagnosis of probable PSP was finally made. CONCLUSIONS Several etiologies, including PSP, should be considered in appropriate clinical contexts if gait examination demonstrates a higher-order gait disorder.
Collapse
Affiliation(s)
- R Ghosh
- Burdwan Medical College and Hospital, Burdwan, India
| | - M León-Ruiz
- Hospital Universitario La Paz, Madrid, España
| | - S Dubey
- Institute of Post Graduate Medical Education and Research and SSKM Hospital , Kolkata, India
| | - A Chakraborty
- Institute of Post Graduate Medical Education and Research and SSKM Hospital , Kolkata, India
| | - J Benito-León
- Universidad Complutense de Madrid, Madrid, España
- Hospital Universitario 12 de Octubre, Madrid, España
- CIBERNED. Centro de Investigación Biomédica en Red Enfermedades Neurodegenerativas, Madrid, España
| |
Collapse
|
10
|
Patra S, Dey J, Chakraborty A. Physicochemical Characterization, Stability, and In Vitro Evaluation of Curcumin-Loaded Solid Lipid Nanoparticles Prepared Using Biocompatible Synthetic Lipids. ACS Appl Bio Mater 2023. [PMID: 37403739 DOI: 10.1021/acsabm.3c00252] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/06/2023]
Abstract
Solid lipid nanoparticles (SLNs) are promising drug delivery vehicles for the delivery of various drugs, especially poorly water-soluble drugs. However, the aqueous stability, drug release, and biocompatibility of SLNs are some of the issues that need attention. In this work, curcumin-loaded SLNs were prepared, and morphology, particle size, and entrapment efficiency were studied. For this, two amino acid-derived lipids were developed. The effect of the polarity of the lipid head on the aqueous stability of the SLN dispersion was investigated. Based on the stability, particle size, and polydispersity, an optimum formulation was obtained. The curcumin entrapment efficiency of the SLNs was found to be greater than those reported in the literature. The entrapped curcumin, as well as curcumin-loaded SLN suspensions, exhibited improved storage stability. The in vitro release kinetics indicated an enhanced rate of drug release in the case of curcumin-loaded SLNs consisting of the lipid containing -OH groups at the lipid head. The pure lipid and the blank SLN were found to have no significant cytotoxicity, but curcumin and curcumin-loaded SLNs induced cell death in a concentration-dependent manner in both human prostatic adenocarcinoma PC3 cell line and human breast carcinoma MCF7 cell line. This study has proposed a potential semisynthetic lipid for the stable SLN suspension for the delivery of curcumin.
Collapse
Affiliation(s)
- Swagata Patra
- Department of Chemistry, Indian Institute of Technology Kharagpur, Kharagpur 721302, India
| | - Joykrishna Dey
- Department of Chemistry, Indian Institute of Technology Kharagpur, Kharagpur 721302, India
| | - Avik Chakraborty
- Radiation Medicine Centre, Bhabha Atomic Research Centre, Parel, Mumbai 400012, India
| |
Collapse
|
11
|
Bhattacharjee D, Chakraborty A. Unusual presentation of Dhat syndrome: A case series. Indian J Psychiatry 2023; 65:604-605. [PMID: 37397853 PMCID: PMC10309260 DOI: 10.4103/indianjpsychiatry.indianjpsychiatry_58_23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/30/2023] [Revised: 04/03/2023] [Accepted: 04/11/2023] [Indexed: 07/04/2023] Open
Affiliation(s)
- Debanjan Bhattacharjee
- Department of Psychiatry, ESI-PGIMSR, ESIC Medical College and ESIC Hospital and ODC (EZ), Joka, Kolkata, West Bengal, India. E-mail:
| | - Avik Chakraborty
- Department of Psychiatry, ESI-PGIMSR, ESIC Medical College and ESIC Hospital and ODC (EZ), Joka, Kolkata, West Bengal, India. E-mail:
| |
Collapse
|
12
|
Chakraborty A, Muranjan M, Karande S, Kharkar V. Porphyrias: Uncommon disorders masquerading as common childhood diseases. J Postgrad Med 2023:374441. [PMID: 37082991 PMCID: PMC10394526 DOI: 10.4103/jpgm.jpgm_698_22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/22/2023] Open
Abstract
Porphyrias are a rare group of inborn errors of metabolism due to defects in the heme biosynthetic pathway. The biochemical hallmark is the overproduction of porphyrin precursors and porphyrin species. Afflicted patients present with a myriad of symptoms causing a diagnostic odyssey. Symptoms often overlap with those of common diseases and may be overlooked unless there is heightened clinical suspicion. We are reporting clinical features and diagnostic challenges in four pediatric patients having variegate porphyria, congenital erythropoietic porphyria, acute intermittent porphyria, and erythropoietic protoporphyria (EPP), who presented with diverse multisystem manifestations. This case series illustrates a logical analysis of symptoms and judicious selection of investigations and the role of genotyping in successfully diagnosing porphyrias.
Collapse
Affiliation(s)
- A Chakraborty
- Genetic Clinic, Department of Pediatrics, Seth G.S. Medical College and K.E.M. Hospital, Parel, Mumbai, Maharashtra, India
| | - M Muranjan
- Genetic Clinic, Department of Pediatrics, Seth G.S. Medical College and K.E.M. Hospital, Parel, Mumbai, Maharashtra, India
| | - S Karande
- Genetic Clinic, Department of Pediatrics, Seth G.S. Medical College and K.E.M. Hospital, Parel, Mumbai, Maharashtra, India
| | - V Kharkar
- Department of Dermatology, Seth G.S. Medical College and K.E.M. Hospital, Parel, Mumbai, Maharashtra, India
| |
Collapse
|
13
|
Das S, Sahu S, Chakraborty A, Kamaleshwaran KK, Bannore TU, Damle A, Chakravarty R, Chakraborty S. A robust lyophilized kit for convenient one-step formulation of [ 68Ga]Ga-DOTA-E-[c(RGDfK)] 2 in hospital radiopharmacy for clinical PET imaging. Appl Radiat Isot 2023; 196:110725. [PMID: 36878089 DOI: 10.1016/j.apradiso.2023.110725] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2022] [Revised: 01/19/2023] [Accepted: 02/14/2023] [Indexed: 02/18/2023]
Abstract
The present article describes the development of robust lyophilized kit for convenient formulation of [68Ga]Ga-DOTA-E-[c(RGDfK)]2 (E = glutamic acid, R = arginine, G = glycine, D = aspartic acid, f = phenylalanine, K = lysine) radiopharmaceutical for clinical use in non-invasive monitoring of malignancies overexpressing integrin αvβ3 receptors. Five batches of the kit were prepared with optimized kit contents, all of which showed high 68Ga-radiolabeling yield (>98%). Pre-clinical evaluation of the [68Ga]Ga-radiotracer in SCID mice bearing FTC133 tumour exhibited significant accumulation in the tumor xenograft. Preliminary human clinical investigation carried out in a 60 year old male patient with metastatic lung cancer revealed high radiotracer uptake in the tumor along with satisfactory target to non-target contrast. The developed kit formulation also showed a long shelf-life of at least 12 months on storage at 0 °C. All these results point towards the promising attributes of the developed kit formulation for convenient preparation of [68Ga]Ga-DOTA-E-[c(RGDfK)]2 for routine clinical use.
Collapse
Affiliation(s)
- Soumen Das
- Radiopharmaceuticals Program, Board of Radiation and Isotope Technology, Navi Mumbai, India; Homi Bhabha National Institute, Mumbai, India
| | - Sudeep Sahu
- Radiation Medicine Centre, Bhabha Atomic Research Centre, Mumbai, India
| | - Avik Chakraborty
- Homi Bhabha National Institute, Mumbai, India; Radiation Medicine Centre, Bhabha Atomic Research Centre, Mumbai, India
| | - K K Kamaleshwaran
- Department of Nuclear Medicine and PET, Kovai Medical Centre and Hospital, Coimbatore, India
| | | | - Archana Damle
- Homi Bhabha National Institute, Mumbai, India; Radiation Medicine Centre, Bhabha Atomic Research Centre, Mumbai, India
| | - Rubel Chakravarty
- Homi Bhabha National Institute, Mumbai, India; Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, India
| | - Sudipta Chakraborty
- Homi Bhabha National Institute, Mumbai, India; Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, India.
| |
Collapse
|
14
|
Banik B, Alam S, Chakraborty A. Comparative study between GRA and MEREC technique on an agricultural-based MCGDM problem in pentagonal neutrosophic environment. Int J Environ Sci Technol (Tehran) 2023; 20:1-16. [PMID: 36817165 PMCID: PMC9928147 DOI: 10.1007/s13762-023-04768-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 10/11/2021] [Revised: 12/16/2022] [Accepted: 01/06/2023] [Indexed: 06/18/2023]
Abstract
In this research article, an improved Multi-criteria group decision-making (MCGDM) strategy has been developed in pentagonal neutrosophic environment incorporating grey relational analysis and method on the removal effects of criteria (MEREC) techniques to address the relative advantages and disadvantages of these aspects in MCGDM. The aim of the study is to improve MCGDM technique which can capture the underlying uncertainties in robust way and can produce consistent results in a more rigorous way. Here, the conception of Hamming distance between two pentagonal neutrosophic number (PNN)s is introduced and the weighted arithmetic and geometric averaging operators in PNN arena are deployed to craft our computational technique more progressive and robust. An agriculture-based numerical problem is illustrated to demonstrate the ranking results of the alternatives by both of the techniques. After evaluating the problem by two aggregation operators, it is found that "plantation crop" is the best alternative under certain circumstances. Lastly, the sensitivity investigation is performed which reveals that with the appliance of arithmetic and geometric aggregation operators the best ranked alternative preserves its position by both of the ranking methods, which definitely exhibit the consistency and robustness of our executed methodology.
Collapse
Affiliation(s)
- B. Banik
- Department of Mathematics, Indian Institute of Engineering Science and Technology, Shibpur, Howrah, 711103 India
| | - S. Alam
- Department of Mathematics, Indian Institute of Engineering Science and Technology, Shibpur, Howrah, 711103 India
| | - A. Chakraborty
- Department of Engineering Science, Academy of Technology, Adisaptagram, West Bengal 712502 India
| |
Collapse
|
15
|
Patra S, Kancharlapalli S, Chakraborty A, Singh K, Kumar C, Guleria A, Rakshit S, Damle A, Chakravarty R, Chakraborty S. Chelator-Free Radiolabeling with Theoretical Insights and Preclinical Evaluation of Citrate-Functionalized Hydroxyapatite Nanospheres for Potential Use as Radionanomedicine. Ind Eng Chem Res 2023. [DOI: 10.1021/acs.iecr.2c04378] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/11/2023]
Affiliation(s)
- Sourav Patra
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400085, India
- Homi Bhabha National Institute, Anushaktinagar, Mumbai 400094, India
| | | | - Avik Chakraborty
- Radiation Medicine Centre, Bhabha Atomic Research Centre, Parel, Mumbai 400012, India
- Homi Bhabha National Institute, Anushaktinagar, Mumbai 400094, India
| | - Khajan Singh
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400085, India
| | - Chandan Kumar
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400085, India
| | - Apurav Guleria
- Radiation and Photochemistry Division, Bhabha Atomic Research Centre, Parel, Mumbai 400012, India
- Homi Bhabha National Institute, Anushaktinagar, Mumbai 400094, India
| | - Sutapa Rakshit
- Radiation Medicine Centre, Bhabha Atomic Research Centre, Parel, Mumbai 400012, India
| | - Archana Damle
- Radiation Medicine Centre, Bhabha Atomic Research Centre, Parel, Mumbai 400012, India
| | - Rubel Chakravarty
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400085, India
- Homi Bhabha National Institute, Anushaktinagar, Mumbai 400094, India
| | - Sudipta Chakraborty
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Trombay, Mumbai 400085, India
- Homi Bhabha National Institute, Anushaktinagar, Mumbai 400094, India
| |
Collapse
|
16
|
Suman SK, Mukherjee A, Pandey U, Chakraborty A, Rakshit S, Tawate M, Sarma HD. 68Ga-Labeled Trastuzumab Fragments for ImmunoPET Imaging of Human Epidermal Growth Factor Receptor 2 Expression in Solid Cancers. Cancer Biother Radiopharm 2023; 38:38-50. [PMID: 36413344 DOI: 10.1089/cbr.2022.0042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
Background: Trastuzumab, the first humanized antibody approved for therapeutic use has shown promising results for the treatment of patients with human epidermal growth factor receptor 2 (HER2) positive cancers. The aim of this study was to formulate immunoPET agents based on trastuzumab fragments and demonstrate their potential for early diagnosis of HER2-positive tumors. Materials and Methods: F(ab')2 and F(ab') fragments of trastuzumab were prepared by enzymatic digestion and conjugated with chelator NOTA for labeling with 68Ga. For comparison, intact trastuzumab was also radiolabeled. In vitro stability, immunoreactivity, and binding affinity of radio formulations toward HER2 receptors were evaluated by performing in vitro studies in cancer cell lines. Biodistribution and PET imaging studies were performed in animal model bearing tumors. Results: 68Ga-NOTA-F(ab')-trastuzumab, 68Ga-NOTA-F(ab')2-trastuzumab, and 68Ga-NOTA-trastuzumab could be prepared with >98% radiochemical purity (% RCP) and were found to be stable when studied up to 4 h. In vitro binding studies revealed high affinity and specificity of formulations toward HER2 receptors. Specific tumor uptake of 68Ga-NOTA-F(ab')-trastuzumab and 68Ga-NOTA-F(ab')2-trastuzumab in HER2-positive tumors was observed in biodistribution and PET imaging studies. Conclusions: This study describes optimization of protocol for the formulation of 68Ga-NOTA-F(ab')-trastuzumab and 68Ga-NOTA-F(ab')2-trastuzumab for targeting HER2-overexpressing tumors. Further studies with these radioformulations are warranted to confirm their potential as immunoPET agents for management of HER2-positive breast and other solid tumors.
Collapse
Affiliation(s)
- Shishu Kant Suman
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre (BARC), Mumbai, India.,Homi Bhabha National Institute, Anushaktinagar, Mumbai, India
| | - Archana Mukherjee
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre (BARC), Mumbai, India.,Homi Bhabha National Institute, Anushaktinagar, Mumbai, India
| | - Usha Pandey
- Board of Radiation & Isotope Technology, Navi Mumbai, India
| | - Avik Chakraborty
- Homi Bhabha National Institute, Anushaktinagar, Mumbai, India.,Radiation Medicine Centre, BARC, Mumbai, India
| | | | | | - Haladhar Dev Sarma
- Radiation Biology & Health Science Division, Bhabha Atomic Research Centre (BARC), Mumbai, India
| |
Collapse
|
17
|
Chakraborty A, Hazra I, Bhattacharjee D. Schizophrenia Secondary to COVID-19 and Tuberculosis: A Case Series of Post-Infection Schizophrenia. Indian J Psychol Med 2023; 45:102-104. [PMID: 36778610 PMCID: PMC9896123 DOI: 10.1177/02537176221138034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Affiliation(s)
- Avik Chakraborty
- Dept. of Psychiatry, ESI-PGIMSR, ESIC Medical College and ESIC Hospital & ODC (EZ), Joka, Kolkata, West Bengal, India
| | - Indrani Hazra
- Dept. of Radiodiagnosis, ESI-PGIMSR, ESIC Medical College and ESIC Hospital & ODC (EZ), Joka, Kolkata, West Bengal, India
| | - Debanjan Bhattacharjee
- Dept. of Psychiatry, ESI-PGIMSR, ESIC Medical College and ESIC Hospital & ODC (EZ), Joka, Kolkata, West Bengal, India
| |
Collapse
|
18
|
Chakraborty A, Bandyopadhyay U, Bhattacharjee D. An observational study on drug prescribing pattern of psychotropic medication in psychiatry outpatient department of a medical college in Eastern India. Arch Ment Health 2023. [DOI: 10.4103/amh.amh_129_22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/06/2023] Open
|
19
|
Chakraborty S, Patra S, Joshi R, Chakraborty A, Chakravarty R, Ningthoujam R. [177Lu]Lu-labeled NaGdF4:Ho-Yb@m-SiO2 upconversion nanophosphors: synthesis and characterization as a potent theranostic probe. Nucl Med Biol 2022. [DOI: 10.1016/s0969-8051(22)02209-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
20
|
Kumar N, Guleria M, Chakraborty A, Amirdhanayagam J, Bannore TU, Damle A, Sarma HD, Das T. Synthesis and evaluation of [
177
Lu]Lu‐labeled porphyrin loaded PAMAM dendrimer: Impact on tumor uptake and pharmacokinetics. Drug Dev Res 2022; 83:1777-1790. [DOI: 10.1002/ddr.21996] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2022] [Revised: 08/14/2022] [Accepted: 08/26/2022] [Indexed: 11/11/2022]
Affiliation(s)
- Naveen Kumar
- Radiopharmaceuticals Division Bhabha Atomic Research Centre Mumbai Maharashtra India
- Department of Chemical Sciences Homi Bhabha National Institute Mumbai Maharashtra India
| | - Mohini Guleria
- Radiopharmaceuticals Division Bhabha Atomic Research Centre Mumbai Maharashtra India
- Department of Chemical Sciences Homi Bhabha National Institute Mumbai Maharashtra India
| | - Avik Chakraborty
- Radiation Medicine Centre Bhabha Atomic Research Centre Mumbai Maharashtra India
| | | | | | - Archana Damle
- Radiation Medicine Centre Bhabha Atomic Research Centre Mumbai Maharashtra India
| | - Haladhar D. Sarma
- Radiation Biology and Health Sciences Division Bhabha Atomic Research Centre Mumbai Maharashtra India
| | - Tapas Das
- Radiopharmaceuticals Division Bhabha Atomic Research Centre Mumbai Maharashtra India
- Department of Chemical Sciences Homi Bhabha National Institute Mumbai Maharashtra India
| |
Collapse
|
21
|
Chakraborty A, Bhattacharjee D, Bandyopadhyay U. Secondary Koro Presenting as Delusional Disorder: A Case Series. Journal of Psychosexual Health 2022. [DOI: 10.1177/26318318221110188] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Koro, a culture-bound syndrome originating from Southeast Asia is characterized by a perception of acute retraction of the penis, accompanied by an acute panic-like reaction of impending danger or death. Koro-like symptoms are considered variants of classical Koro syndrome and differ from it phenomenologically. We described here a case series of secondary Koro, presenting as a delusional disorder who remitted on treatment with antipsychotics and maintained the improvement on follow-up. It is important to differentiate between classical Koro with Koro-like syndrome, with exploration of any delusional core during clinical assessment for better categorization and management.
Collapse
Affiliation(s)
- Avik Chakraborty
- Department of Psychiatry, ESI-PGMISR, Joka, Kolkata, West Bengal, India
| | | | | |
Collapse
|
22
|
Debnath G, Chakraborty A. A Study on FibroScan and Endoscopic Finding in Patients of Chronic Liver Disease attending Tripura Medical College and Dr. B.R. Ambedkar Memorial Teaching Hospital. J Assoc Physicians India 2022; 70:11-12. [PMID: 35702844 DOI: 10.5005/japi-11001-0018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
INTRODUCTION Chronic liver disease (CLD) represents different liver disorders of varying severity and etiology in which hepatic inflammation and fibrosis continue at least for 6 months. Portal hypertension is one of the important complications of CLD and its early recognition is of paramount importance. Though liver biopsy remains the gold standard for diagnosing liver fibrosis and upper gastrointestinal (GI) endoscopy plays an important role in diagnosing different findings of portal hypertension, various noninvasive methods like FibroScan are being increasingly used to diagnose liver fibrosis. AIMS AND OBJECTIVES Study the FibroScan and endoscopic findings in patients of CLDs and the objectives are to find the prevalence of portal hypertension and to find various grades of esophageal varix and portal hypertensive gastropathy (PHG) and its relationship with liver fibrosis by FibroScan. MATERIALS AND METHODS A total of 114 patients of CLD and compensated cirrhosis having childturcotte- pugh (CTP) stages A and B were included in the study fulfilling inclusion and exclusion criteria, after calculating the sample size of 100. All the patients underwent detailed history, physical and gastrointestinal examination. Complete blood count (CBC), liver function test (LFT), kidney function test (KFT), viral markers were done. Aspartate aminotransferase (AST) to platelet ratio index (APRI) score was calculated, liver fibrosis was estimated by FibroScan and evidence of portal hypertension was documented by upper GI endoscopy. Cutoff value of FibroScan, APRI score, and model for end-stage liver disease (MELD) score for portal hypertension was decided by receiver operating characteristic (ROC) curve. RESULTS Alcoholic liver disease (ALD) was the most common cause (43%) of CLD closely followed by nonalcoholic fatty liver disease (NAFLD) in 42% cases followed by chronic viral hepatitis, 75% patients had evidence of portal hypertension with PHG being the most common followed by esophageal varix. F4 fibrosis was found in 73% of cases followed by F3, F2, and F1 fibrosis. FibroScan value of 12.2 kPa was predictive of presence of portal hypertension and value of 26.6 mm predicted the presence of large esophageal varices.
Collapse
Affiliation(s)
- Goutam Debnath
- Postgraduate Trainee; Tripura Medical College and Dr. B.R. Ambedkar Memorial Teaching Hospital, Tripura, Agartala, India
| | - Avik Chakraborty
- Professor, Tripura Medical College and Dr. B.R. Ambedkar Memorial Teaching Hospital, Tripura, Agartala, India; Corresponding Author
| |
Collapse
|
23
|
Menon SR, Mitra A, Chakraborty A, Tawate M, Sahu S, Rakshit S, Gaikwad S, Dhotre G, Damle A, Banerjee S. Clinical Dose Preparation of [ 177Lu]Lu-DOTA-Pertuzumab Using Medium Specific Activity [ 177Lu]LuCl 3 for Radioimmunotherapy of Breast and Epithelial Ovarian Cancers, with HER2 Receptor Overexpression. Cancer Biother Radiopharm 2022; 37:384-402. [PMID: 35575711 DOI: 10.1089/cbr.2021.0230] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Background: The overexpression of human epidermal growth factor receptor 2 (HER2) is commonly associated with metastatic breast cancer and epithelial ovarian cancer. The U.S. Food and Drug Administration (FDA) has approved Trastuzumab as an anti-HER2 agent for the metastatic breast and epithelial ovarian cancer. However, Trastuzumab has severe limitations in the treatment of metastatic breast cancer associated with ligand-dependent dimerization of HER2 receptor at the extracellular domain-II (ECD-II) region. The therapeutic approach in combination of pertuzumab and trastuzumab is found to be effective in preventing HER2 dimerization at the ECD-II region. The radioimmunotherapeutic approach, utilizing both these anti-HER2 agents (trastuzumab/pertuzumab), radiolabeled with [177Lu]Lu3+, has proved to be clinically efficacious with promising potential. Toward this, the formulation for clinical doses of [177Lu]Lu-DOTA-pertuzumab has been optimized using medium specific activity (0.81 GBq/μg) [177Lu]LuCl3. Materials and Methods: Preconcentrated pertuzumab was conjugated with p-NCS-benzyl-DOTA. Purified DOTA-benzyl-pertuzumab conjugate was radiolabeled with carrier-added [177Lu]LuCl3. Quality control parameters were evaluated for the [177Lu]Lu-DOTA-pertuzumab. In vivo biodistribution was carried out at different time points postadministration. Specific cell binding, immunoreactivity, and internalization were investigated by using SKOV3 and SKBR3 cells. Results: In this study, the authors reported a consistent and reproducible protocol for clinical dose formulations of [177Lu]Lu-DOTA-pertuzumab, with a radiochemical yield of 86.67% ± 1.03% and radiochemical purity (RCP) of 99.36% ± 0.36% (n = 10). Preclinical cell binding studies of [177Lu]Lu-DOTA-pertuzumab revealed specific binding with SKOV3 and SKBR3 cells up to 24.4% ± 1.4% and 23.2% ± 0.8%, respectively. The uptakes in SKOV3- and SKBR3-xenografted tumor in severe combined immunodeficiency mice were observed to be 25.9% ± 0.8% and 25.2% ± 1.2% ID/g at 48 and 120 h postinjection, respectively. Conclusions: A protocol was optimized for the preparation of ready-to-use clinical dose of [177Lu]Lu-DOTA-pertuzumab, in hospital radiopharmacy settings. The retention of RCP of the radiopharmaceutical, on storage in saline and serum, at -20°C, up to 120 h postradiolabeling, confirmed its in vitro stability.
Collapse
Affiliation(s)
- Sreeja Raj Menon
- Health Physics Division, Bhabha Atomic Research Centre, Mumbai, India.,Homi Bhabha National Institute, Mumbai, India
| | - Arpit Mitra
- Medical Cyclotron Facility, Board of Radiation and Isotope Technology, Mumbai, India
| | - Avik Chakraborty
- Homi Bhabha National Institute, Mumbai, India.,Radiation Medicine Centre, Bhabha Atomic Research Centre, Mumbai, India
| | - Megha Tawate
- Radiation Medicine Centre, Bhabha Atomic Research Centre, Mumbai, India
| | - Sudeep Sahu
- Radiation Medicine Centre, Bhabha Atomic Research Centre, Mumbai, India
| | - Sutapa Rakshit
- Radiation Medicine Centre, Bhabha Atomic Research Centre, Mumbai, India
| | - Sujay Gaikwad
- Homi Bhabha National Institute, Mumbai, India.,Radiation Medicine Centre, Bhabha Atomic Research Centre, Mumbai, India
| | - Geetanjali Dhotre
- Department of Chemical Sciences, Tata Institute of Fundamental Research, Mumbai, India
| | - Archana Damle
- Homi Bhabha National Institute, Mumbai, India.,Radiation Medicine Centre, Bhabha Atomic Research Centre, Mumbai, India
| | - Sharmila Banerjee
- Homi Bhabha National Institute, Mumbai, India.,Radiological Research Unit, Advance Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, India
| |
Collapse
|
24
|
Tawate M, Mitra A, Chakraborty A, Lad S, Gaikwad S, Sahu S, Rakshit S, Menon S, Ray MK, Damle A, Banerjee S. Radiochemical formulation of 177Lu-DOTA-trastuzumab: using low specific activity 177LuCl3. Nucl Med Biol 2022. [DOI: 10.1016/s0969-8051(22)00313-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
25
|
Tawate M, Chakraborty A, Mitra A, Lad S, Gaikwad S, Sahu S, Upadhye T, Rakshit S, Menon S, Ray MK, Damle A, Banerjee S. In vitro study of 177Lu-DOTA-Trastuzumab and 177Lu-DOTA-Pertuzumab for evaluation of binding affinity towards human cell lines with differential expression of HER-2 receptor. Nucl Med Biol 2022. [DOI: 10.1016/s0969-8051(22)00437-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
26
|
Tawate M, Sahu S, Chakraborty A, Lad S, Gaikwad S, Mitra A, Upadhye T, Menon S, Damle A, Banerjee S. Comparative evaluation of 177Lu-DOTATATE and 90Y-DOTATATE in SSTR II overexpressing Xenograft models for treatment of variable volume neuroendocrine tumours. Nucl Med Biol 2022. [DOI: 10.1016/s0969-8051(22)00438-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
27
|
Mitra A, Chakraborty A, Upadhye T, Tawate M, Lad S, Sahu S, Rajesh C, Bagul S, Pawar Y, Ray MK, Banerjee S. Automated Radiochemical Synthesis of Pharmaceutical Grade [
18
F]FLT using 3‐N‐Boc‐5’‐O‐dimethoxytrityl‐3’‐O‐nosyl‐thymidine precursor and its Sep‐Pak® Purification employing Selective Elution from Reversed Phase. J Labelled Comp Radiopharm 2022; 65:206-222. [DOI: 10.1002/jlcr.3974] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2022] [Revised: 04/18/2022] [Accepted: 04/20/2022] [Indexed: 11/06/2022]
Affiliation(s)
- Arpit Mitra
- Radiopharmaceuticals Laboratory, Board of Radiation and Isotope Technology, Vashi Navi Mumbai India
| | - Avik Chakraborty
- Radiation Medicine Centre, Bhabha Atomic Research Centre, Parel Mumbai India
- Homi Bhabha National Institute Mumbai India
| | - Trupti Upadhye
- Radiation Medicine Centre, Bhabha Atomic Research Centre, Parel Mumbai India
| | - Megha Tawate
- Radiation Medicine Centre, Bhabha Atomic Research Centre, Parel Mumbai India
| | - Sangita Lad
- Radiation Medicine Centre, Bhabha Atomic Research Centre, Parel Mumbai India
| | - Sudeep Sahu
- Radiation Medicine Centre, Bhabha Atomic Research Centre, Parel Mumbai India
| | - C. Rajesh
- Radiation Medicine Centre, Bhabha Atomic Research Centre, Parel Mumbai India
| | - Swati Bagul
- Radiation Medicine Centre, Bhabha Atomic Research Centre, Parel Mumbai India
| | - Yogita Pawar
- Radiation Medicine Centre, Bhabha Atomic Research Centre, Parel Mumbai India
| | - Mukti Kant Ray
- Radiation Medicine Centre, Bhabha Atomic Research Centre, Parel Mumbai India
- Homi Bhabha National Institute Mumbai India
| | - Sharmila Banerjee
- Homi Bhabha National Institute Mumbai India
- Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre Navi Mumbai India
| |
Collapse
|
28
|
Das S, Chakraborty A, Chandra S. Psychosocial perception of health-care workers in a COVID-19-designated hospital in eastern India. J Educ Health Promot 2022; 11:17. [PMID: 35281371 PMCID: PMC8893095 DOI: 10.4103/jehp.jehp_526_21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Received: 04/19/2021] [Accepted: 05/20/2021] [Indexed: 05/14/2023]
Abstract
BACKGROUND COVID-19 pandemic has changed the life of people in many facets, economic, social, and psychological. Frontline health-care workers (HCWs) fighting against this pandemic faced some psychological as well as social issues which are of major concern. The objective of the study is to evaluate the magnitude of mental health problems, namely depression, anxiety, and stress among frontline HCWs as well as their perception on ongoing events and surroundings. MATERIALS AND METHODS It was a prospective, observational study on n = 85 HCWs over a 4-month period. Study participants were sampled purposively in accordance with inclusion and exclusion criteria; data were collected by online survey method. A semi-structured scale was used: Part A of which assessed the demography and perception of HCWs on surrounding along with ongoing social events and Part B consisted of the Depression, Anxiety, and Stress Scale-21 that was used to assess mental health issues. All the associations were tested in percentages and proportions. Statistics was calculated by using SPSS 24th version. RESULTS Majority of the participants were female doctors and belonged to 21-30 years' age group. Most of them were marginally worried of contacting infection (73%) but were substantially apprehensive of transmitting infection to their family (56.5%) and hoped positive outcome ultimately in the form of recovery from infection. Majority (96.4%) gathered information from authentic sources and were confident of adequacy of their knowledge. Majority (88.3%) were satisfied about their occupational safety and responded on scientific solution of pandemic. However, we got a mixed result about their professional appreciation. Depression symptom score was higher than anxiety and stress symptom score in our participants. CONCLUSIONS Doctors and nurses both were suffering from mental health issues, and provision of adequate information and occupational safety may lessen these burdens.
Collapse
Affiliation(s)
- Subrata Das
- Department of Obstetrics and Gynaecology, ESI PGI MSR, ESIC Medical College and ESIC Hospital and ODC (EZ), Kolkata, West Bengal, India
| | - Avik Chakraborty
- Department of Psychiatry, ESI PGI MSR, ESIC Medical College and ESIC Hospital and ODC (EZ), Kolkata, West Bengal, India
- Address for correspondence: Dr. Avik Chakraborty, C/O Subrata Das, J/6, Banerjee Para, Kamdahari, Garia, Kolkata - 700 084, West Bengal, India. E-mail:
| | - Samatirtha Chandra
- Department of Microbiology, ESI PGI MSR, ESIC Medical College and ESIC Hospital and ODC (EZ), Kolkata, West Bengal, India
| |
Collapse
|
29
|
Azizi A, Camblong H, Chakraborty A, Ordóñez C, Scully M. Quantum optics meets black hole thermodynamics via conformal quantum mechanics: II. Thermodynamics of acceleration radiation. Int J Clin Exp Med 2021. [DOI: 10.1103/physrevd.104.084085] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
30
|
Phadnis S, Sengupta S, Chakraborty A. Work From Home, Mental Health and Employee Needs: A pilot study in selected information technology organizations in India. APJHM 2021. [DOI: 10.24083/apjhm.v16i3.977] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Introduction: The Coronavirus (COVID-19) pandemic has impacted the economy and has resulted in changes to the working arrangements of employees who are based at home and may continue to work from home (WFH). Organizations are expected to develop an inclusive policy for their employees to promote mental health whilst working from home. The aim of this study was to document the impact of WFH on mental health and determine the expectations of employees from their organizations regarding occupational health policy.
Methodology: A cross-sectional study was conducted on the impact of work from home on mental health and to document the mental health support needs of employees. Google form was floated through social media platform to receive the responses. A total of 74 responses were received. Descriptive analysis was conducted using Microsoft Excel, while qualitative answers were manually analysed.
Results: About 67% employees (n=45) mentioned that their workload has increased significantly during work from home. Thirty five percent (n=26) felt lonely and lost and 47% (n= 34) felt disconnected from the real world, indicating the mental health impact of work from home. Fifty three percent employees (n=40) mentioned that there were no efforts made by their organization to reduce the mental health impact of work from home.
Conclusion: The results of this study indicate that there is an urgent need to create a comprehensive occupational health and safety policy inclusive of strategies to improve mental health by the organizations in light of “work from home” as a “new-normal”.
Collapse
|
31
|
Azizi A, Camblong H, Chakraborty A, Ordóñez C, Scully M. Acceleration radiation of an atom freely falling into a Kerr black hole and near-horizon conformal quantum mechanics. Int J Clin Exp Med 2021. [DOI: 10.1103/physrevd.104.065006] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
32
|
Chakraborty A, Mitra A, Tawate M, Sahoo S, Lad S, Rakshit S, Gaikwad S, Basu S, Shimpi H, Banerjee S. Therapeutic Multidose Preparation of a Ready-to-Use 177Lu-PSMA-617 Using Carrier Added Lutetium-177 in a Hospital Radiopharmacy and Its Clinical Efficacy. Cancer Biother Radiopharm 2021; 36:682-692. [PMID: 34402687 DOI: 10.1089/cbr.2020.4261] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
Introduction: [177Lu]Lu-prostate-specific membrane antigen (PSMA)-617 has emerged as a promising radiopharmaceutical for targeting PSMA in metastatic castrate-resistant prostate carcinoma (mCRPC). We have optimized the radiolabeling protocol for a multidose formulation (27-28.8 GBq equivalent to 6-7 patient-doses) of [177Lu]Lu-PSMA-617 using [177Lu]Lu3+ produced via 176Lu(n,γ)177Lu route with moderate specific activity (0.66-0.81 GBq/μg). Methods: [177Lu]Lu-PSMA-617 was synthesized using moderate specific activity [177Lu]LuCl3 (0.74 GBq/μg) with PSMA-617 having metal-to-ligand molar ratio ∼1: 2.5 in CH3COONH4 buffer (0.1 M) containing gentisic acid at pH 4.0-4.5. Human prostate carcinoma cell line LNCaP cell (high PSMA expression) was used for in vitro cell-binding studies and generating tumor xenograft models in nude mice for tissue biodistribution studies. Several batches of the present formulation have been clinically administered in mCRPC patients (single patient dose: 4.44-5.55 GBq per cycle). Results: In this study we report a consistent and reproducible protocol for multidose formulations of [177Lu]Lu-PSMA-617 for adopting in a hospital radiopharmacy setting. Although the radiochemical yield of [177Lu]Lu-PSMA-617 was found to be 97.30% ± 1.03%, the radiochemical purity was 98.24% ± 0.50% (n = 19). In vitro and serum stability of [177Lu]Lu-PSMA-617 was retained up to 72 and 120 h after radiolabeling and upon storage at -20°C with a radioactive concentration between 0.37 and 0.74 GBq/mL upon using stabilizer concentration as low as 43-48 μg/mCi. Preclinical cell-binding studies of [177Lu]Lu-PSMA-617 revealed specific binding with LNCaP cells of 17.4% ± 2.4%. The uptake in LnCaP xenografted tumor (nude mice) was 7.5 ± 2.6% ID/g for ∼1.5-2.0 cm3 tumor volume at 24-h post-injection. Post-therapy (24 h) SPECT image of mCRPC patients with prior orchidectomy and various hormone therapy showed specific localization of [177Lu]Lu-PSMA-617 in the tumor region. Conclusions: Formulation of a ready-to-use multidose formulation of [177Lu]Lu-PSMA-617 was successfully achieved and the procedure was optimized for routine preparation at a hospital radiopharmacy set-up. High degree of localization of [177Lu]Lu-PSMA-617 in post-therapy SPECT scan and the post-therapeutic response confirms its therapeutic efficacy. Clinical Trials.gov ID: RPC/51/Minutes/Final dated 16th October, 2019.
Collapse
Affiliation(s)
- Avik Chakraborty
- Radiation Medicine Centre, Bhabha Atomic Research Centre, Mumbai, India.,Department of Atomic Energy, Homi Bhabha National Institute, Mumbai, India
| | - Arpit Mitra
- Medical Cyclotron Facility, Radiation Medicine Centre, Board of Radiation and Isotope Technology, Mumbai, India
| | - Megha Tawate
- Radiation Medicine Centre, Bhabha Atomic Research Centre, Mumbai, India
| | - Sudip Sahoo
- Radiation Medicine Centre, Bhabha Atomic Research Centre, Mumbai, India
| | - Sangita Lad
- Radiation Medicine Centre, Bhabha Atomic Research Centre, Mumbai, India
| | - Sutapa Rakshit
- Radiation Medicine Centre, Bhabha Atomic Research Centre, Mumbai, India
| | - Sujay Gaikwad
- Radiation Medicine Centre, Bhabha Atomic Research Centre, Mumbai, India.,Department of Atomic Energy, Homi Bhabha National Institute, Mumbai, India
| | - Sandip Basu
- Radiation Medicine Centre, Bhabha Atomic Research Centre, Mumbai, India.,Department of Atomic Energy, Homi Bhabha National Institute, Mumbai, India
| | - Hemant Shimpi
- Radiation Medicine Centre, Bhabha Atomic Research Centre, Mumbai, India
| | - Sharmila Banerjee
- Radiation Medicine Centre, Bhabha Atomic Research Centre, Mumbai, India.,Department of Atomic Energy, Homi Bhabha National Institute, Mumbai, India.,Medical Cyclotron Facility, Radiation Medicine Centre, Board of Radiation and Isotope Technology, Mumbai, India
| |
Collapse
|
33
|
Chakraborty A, Pang J, Chan D, Watts G. Effectiveness of proprotein convertase subtilisin/kexin-9 monoclonal antibody treatment on plasma lipoprotein(a) in patients with elevated lipoprotein(a) attending a clinic. Atherosclerosis 2021. [DOI: 10.1016/j.atherosclerosis.2021.06.353] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
34
|
Chakraborty A, Chakraborty S, Sen S, Bhatacharya T, Khemka R. Modification of the sacral erector spinae plane block using an ultrasound-guided sacral foramen injection: dermatomal distribution and radiocontrast study. Anaesthesia 2021; 76:1538-1539. [PMID: 34309009 DOI: 10.1111/anae.15549] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/01/2021] [Indexed: 11/27/2022]
Affiliation(s)
| | | | - S Sen
- Tata Medical Center, Kolkata, India
| | | | - R Khemka
- Tata Medical Center, Kolkata, India
| |
Collapse
|
35
|
Toigo V, Marcuzzi D, Serianni G, Boldrin M, Chitarin G, Bello SD, Grando L, Luchetta A, Pasqualotto R, Zaccaria P, Zanotto L, Agnello R, Agostinetti P, Agostini M, Antoni V, Aprile D, Barbisan M, Battistella M, Berton G, Bigi M, Brombin M, Candeloro V, Canton A, Casagrande R, Cavallini C, Cavazzana R, Cordaro L, Cruz N, Palma MD, Dan M, De Lorenzi A, Delogu R, De Muri M, Denizeau S, Fadone M, Fellin F, Ferro A, Gaio E, Gasparini F, Gasparrini C, Gnesotto F, Jain P, Krastev P, Lopez-Bruna D, Lorenzini R, Maistrello A, Manduchi G, Manfrin S, Marconato N, Martines E, Martini G, Martini S, Milazzo R, Patton T, Pavei M, Peruzzo S, Pilan N, Pimazzoni A, Poggi C, Pomaro N, Pouradier-Duteil B, Recchia M, Rigoni-Garola A, Rizzolo A, Sartori E, Shepherd A, Siragusa M, Sonato P, Sottocornola A, Spada E, Spagnolo S, Spolaore M, Taliercio C, Terranova D, Tinti P, Tomsič P, Trevisan L, Ugoletti M, Valente M, Vignando M, Zagorski R, Zamengo A, Zaniol B, Zaupa M, Zuin M, Cavenago M, Boilson D, Rotti C, Veltri P, Decamps H, Dremel M, Graceffa J, Geli F, Urbani M, Zacks J, Bonicelli T, Paolucci F, Garbuglia A, Agarici G, Gomez G, Gutierrez D, Kouzmenko G, Labate C, Masiello A, Mico G, Moreno JF, Pilard V, Rousseau A, Simon M, Kashiwagi M, Tobari H, Watanabe K, Maejima T, Kojima A, Oshita E, Yamashita Y, Konno S, Singh M, Chakraborty A, Patel H, Singh N, Fantz U, Bonomo F, Cristofaro S, Heinemann B, Kraus W, Wimmer C, Wünderlich D, Fubiani G, Tsumori K, Croci G, Gorini G, McCormack O, Muraro A, Rebai M, Tardocchi M, Giacomelli L, Rigamonti D, Taccogna F, Bruno D, Rutigliano M, D'Arienzo M, Tonti A, Panin F. On the road to ITER NBIs: SPIDER improvement after first operation and MITICA construction progress. Fusion Engineering and Design 2021. [DOI: 10.1016/j.fusengdes.2021.112622] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
36
|
Kushwaha K, Mitra A, Chakraborty A, Keshavkumar B, Tawate M, Lad S, Upadhye T, Dey MK, Bhoite R, Satpati AK, Banerjee S. On the production of pharmaceutical grade indium-111-chloride in the medical cyclotron from natural cadmium target and its use in formulation of diagnostic patient dose of 111In-pentetreotide for imaging somatostatin receptor overexpression. J Radioanal Nucl Chem 2021. [DOI: 10.1007/s10967-021-07652-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
37
|
Chakraborty A, Pang J, Chan D, Watts G. Cardiovascular and behavioural risk factors in families with elevated lipoprotein(a)[Lp(a)]. Eur J Prev Cardiol 2021. [DOI: 10.1093/eurjpc/zwab061.234] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Background/Introduction
Elevated lipoprotein(a)[Lp(a)] is an inherited and independent risk factor for atherosclerotic cardiovascular diseases (ASCVD). However, it is an under detected condition with no specific therapy available at present for lowering Lp(a). Hence, identifying the distribution of modifiable cardiovascular and behavioural risk factors is important for implementing an effective intervention programme to mitigate the overall risk of ASCVD in high-risk individuals with elevated Lp(a).
Purpose
The primary aim was to describe and compare the distribution of modifiable cardiovascular and behavioural risk factors in both index cases and their relatives with elevated Lp(a) identified through cascade testing at the Lipid Disorders Clinic, Royal Perth Hospital.
Methods
We studied 51 index cases and 71 relatives cascade tested with elevated Lp(a) (≥0.5 g/L). Questionnaires were completed concerning aspects of cardiovascular health (cholesterol level, blood pressure and blood glucose level) and behavioural health metrics (diet, smoking, physical activity, body-mass-index [BMI]). Lp(a) was measured by an immunoassay having minimal dependence on apolipoprotein(a) isoform size. The health metrics were described as proportions and statistical analyses performed using Student’s t-test or Chi-square where appropriate.
Results
Compared with the index cases, a higher proportion of their affected relatives were female (62% vs 43%, p = 0.039), younger (43 years vs 53 years, p < 0.001) and had lower Lp(a) levels (1.03 g/L vs 1.12 g/L, p = 0.003). A lower proportion of the affected relatives were treated for dyslipidaemia (31% vs 96%, p < 0.001). The affected relatives also had a lower incidence of ASCVD events (3% vs 37%, p < 0.001), hypertension (21% vs 43%, p = 0.003), and lower HbA1c levels (5.3% vs 5.9%, p = 0.031) compared with index cases. Additionally, a larger proportion of the affected relatives had ideal cardiovascular health (35% vs 14%, p = 0.008) compared with their index cases. However, more than half of the index cases and their relatives did not maintain a healthy diet (59% and 69%, respectively) and an ideal BMI (68% and 59%, respectively).
Conclusion(s)
Although the younger affected relatives with elevated Lp(a) have a lower cardiovascular risk compared with the index cases, a focus on modifiable behavioural changes, such as a healthy diet and an ideal body weight, is still required to mitigate the overall risk of ASCVD.
Collapse
Affiliation(s)
| | - J Pang
- University of Western Australia, Perth, Australia
| | - D Chan
- University of Western Australia, Perth, Australia
| | - G Watts
- Royal Perth Hospital, Lipid Disorders Clinic, Internal Medicine, Department of Cardiology, Perth, Australia
| |
Collapse
|
38
|
Jurgilas S, Chakraborty A, Rich CJH, Caldwell L, Williams HJ, Fitch NJ, Sauer BE, Frye MD, Hutson JM, Tarbutt MR. Collisions between Ultracold Molecules and Atoms in a Magnetic Trap. Phys Rev Lett 2021; 126:153401. [PMID: 33929220 DOI: 10.1103/physrevlett.126.153401] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/05/2021] [Revised: 02/19/2021] [Accepted: 03/04/2021] [Indexed: 06/12/2023]
Abstract
We prepare mixtures of ultracold CaF molecules and Rb atoms in a magnetic trap and study their inelastic collisions. When the atoms are prepared in the spin-stretched state and the molecules in the spin-stretched component of the first rotationally excited state, they collide inelastically with a rate coefficient k_{2}=(6.6±1.5)×10^{-11} cm^{3}/s at temperatures near 100 μK. We attribute this to rotation-changing collisions. When the molecules are in the ground rotational state we see no inelastic loss and set an upper bound on the spin-relaxation rate coefficient of k_{2}<5.8×10^{-12} cm^{3}/s with 95% confidence. We compare these measurements to the results of a single-channel loss model based on quantum defect theory. The comparison suggests a short-range loss parameter close to unity for rotationally excited molecules, but below 0.04 for molecules in the rotational ground state.
Collapse
Affiliation(s)
- S Jurgilas
- Centre for Cold Matter, Blackett Laboratory, Imperial College London, Prince Consort Road, London SW7 2AZ, United Kingdom
| | - A Chakraborty
- Centre for Cold Matter, Blackett Laboratory, Imperial College London, Prince Consort Road, London SW7 2AZ, United Kingdom
| | - C J H Rich
- Centre for Cold Matter, Blackett Laboratory, Imperial College London, Prince Consort Road, London SW7 2AZ, United Kingdom
| | - L Caldwell
- Centre for Cold Matter, Blackett Laboratory, Imperial College London, Prince Consort Road, London SW7 2AZ, United Kingdom
| | - H J Williams
- Centre for Cold Matter, Blackett Laboratory, Imperial College London, Prince Consort Road, London SW7 2AZ, United Kingdom
| | - N J Fitch
- Centre for Cold Matter, Blackett Laboratory, Imperial College London, Prince Consort Road, London SW7 2AZ, United Kingdom
| | - B E Sauer
- Centre for Cold Matter, Blackett Laboratory, Imperial College London, Prince Consort Road, London SW7 2AZ, United Kingdom
| | - Matthew D Frye
- Joint Quantum Centre (JQC) Durham-Newcastle, Department of Chemistry, Durham University, South Road, Durham DH1 3LE, United Kingdom
| | - Jeremy M Hutson
- Joint Quantum Centre (JQC) Durham-Newcastle, Department of Chemistry, Durham University, South Road, Durham DH1 3LE, United Kingdom
| | - M R Tarbutt
- Centre for Cold Matter, Blackett Laboratory, Imperial College London, Prince Consort Road, London SW7 2AZ, United Kingdom
| |
Collapse
|
39
|
Singla R, Singhal R, Rathore R, Gupta A, Sethi P, Myneedu VP, Chakraborty A, Kumar V. Risk factors for chronic pulmonary aspergillosis in post-TB patients. Int J Tuberc Lung Dis 2021; 25:324-326. [PMID: 33762078 DOI: 10.5588/ijtld.20.0735] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Affiliation(s)
- R Singla
- Department of Tuberculosis and Respiratory Diseases, National Institute of Tuberculosis and Respiratory Diseases, New Delhi, India
| | - R Singhal
- Department of Microbiology, National Institute of Tuberculosis and Respiratory Diseases, New Delhi, India
| | - R Rathore
- Department of Tuberculosis and Respiratory Diseases, National Institute of Tuberculosis and Respiratory Diseases, New Delhi, India
| | - A Gupta
- Department of Tuberculosis and Respiratory Diseases, National Institute of Tuberculosis and Respiratory Diseases, New Delhi, India
| | - P Sethi
- Department of Tuberculosis and Respiratory Diseases, National Institute of Tuberculosis and Respiratory Diseases, New Delhi, India
| | - V P Myneedu
- Department of Microbiology, National Institute of Tuberculosis and Respiratory Diseases, New Delhi, India
| | - A Chakraborty
- Department of Tuberculosis and Chest Diseases, National Institute of Tuberculosis and Respiratory Diseases, New Delhi, India
| | - V Kumar
- Department of Tuberculosis and Chest Diseases, National Institute of Tuberculosis and Respiratory Diseases, New Delhi, India
| |
Collapse
|
40
|
Mitra A, Chakraborty A, Gaikwad S, Tawate M, Upadhye T, Lad S, Sahoo S, Jagesia P, Parghane R, Menon S, Basu S, Dhami PS, Banerjee S. On the Separation of Yttrium-90 from High-Level Liquid Waste: Purification to Clinical-Grade Radiochemical Precursor, Clinical Translation in Formulation of 90Y-DOTATATE Patient Dose. Cancer Biother Radiopharm 2021; 36:143-159. [PMID: 33750229 DOI: 10.1089/cbr.2020.4092] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Introduction: The quality control parameters of in-house-produced 90Y-Acetate from high-level liquid waste (HLLW) using supported liquid membrane (SLM) technology were validated and compared with the pharmacopeia standard. The radiolabeling of DOTATATE yielding 90Y-DOTATATE in acceptable radiochemical purity (RCP), with expected pharmacological behavior in in vivo models, establish the quality of 90Y-Acetate. Clinical translation of 90Y-Acetate in formulation of 90Y-DOTATATE adds support toward its use as clinical-grade radiochemical. Methods: Quality control parameters of 90Y-Acetate, namely radionuclide purity (RNP), were evaluated using β- spectrometry, γ-spectroscopy, and liquid scintillation counting. RCP and metallic impurities were established using high-performance liquid chromatography and inductively coupled plasma optical emission spectrometry, respectively. The suitability of 90Y-Acetate as an active pharmaceutical ingredient radiochemical was ascertained by radiolabeling with DOTATATE. In vivo biodistribution of 90Y-DOTATATE was carried out in nude mice bearing AR42J xenografted tumor. Clinical efficacy of 90Y-DOTATATE was established after using in patients with large-volume neuroendocrine tumors (NET). Bremsstrahlung imaging was carried out in dual-head gamma camera with a wide energy window setting (100-250 keV). Results: In-house-produced 90Y-Acetate was clear, colorless, and radioactive concentration (RAC) in the range of 40-50 mCi/mL. RCP was >98%. 90Sr content was <0.85 μCi/Ci of 90Y. Gross λ content was <0.8 nCi/Ci of 90Y and no γ peak was observed. Fe3+, Cu2+, Zn2+, Cd2+, and Pb2+ contents were <1.7 μg/Ci. The radiolabeling yield (RLY) of 90Y-DOTATATE was >94%, RCP was >98%. The in vitro stability of 90Y-DOTATATE was up to 72 h postradiolabeling, upon storage at -20°C. Post-therapy (24 h) Bremsstrahlung image of patients with large NET exhibit complete localization of 90Y-DOTATATE in tumor region. Conclusions: This study demonstrates that the in-house-produced 90Y-Acetate from HLLW can be used for the formulation of various therapeutic 90Y-based radiopharmaceuticals. Since 90Y is an imported radiochemical precursor available at a high cost in India, this study which demonstrates the suitability of indigenously sourced 90Y, ideally exemplifies the recovery of "wealth from waste." The Clinical Trial Registration number: (P17/FEB/2019).
Collapse
Affiliation(s)
- Arpit Mitra
- Medical Cyclotron Facility, Radiation Medicine Center, Board of Radiation and Isotope Technology, Mumbai, India
| | - Avik Chakraborty
- Radiation Medicine Center, Bhabha Atomic Research Center, Mumbai, India.,Homi Bhabha National Institute, Mumbai, India
| | - Sujay Gaikwad
- Radiation Medicine Center, Bhabha Atomic Research Center, Mumbai, India.,Homi Bhabha National Institute, Mumbai, India
| | - Megha Tawate
- Radiation Medicine Center, Bhabha Atomic Research Center, Mumbai, India
| | - Trupti Upadhye
- Radiation Medicine Center, Bhabha Atomic Research Center, Mumbai, India
| | - Sangita Lad
- Radiation Medicine Center, Bhabha Atomic Research Center, Mumbai, India
| | - Sudip Sahoo
- Radiation Medicine Center, Bhabha Atomic Research Center, Mumbai, India
| | - Poonam Jagesia
- Fuel Reprocessing Division, Bhabha Atomic Research Center, Mumbai, India
| | - Rahul Parghane
- Radiation Medicine Center, Bhabha Atomic Research Center, Mumbai, India.,Homi Bhabha National Institute, Mumbai, India
| | - Sreeja Menon
- Health Physics Division, Bhabha Atomic Research Center, Mumbai, India.,Homi Bhabha National Institute, Mumbai, India
| | - Sandip Basu
- Radiation Medicine Center, Bhabha Atomic Research Center, Mumbai, India.,Homi Bhabha National Institute, Mumbai, India
| | - Prem Singh Dhami
- Fuel Reprocessing Division, Bhabha Atomic Research Center, Mumbai, India
| | - Sharmila Banerjee
- Medical Cyclotron Facility, Radiation Medicine Center, Board of Radiation and Isotope Technology, Mumbai, India.,Radiation Medicine Center, Bhabha Atomic Research Center, Mumbai, India.,Homi Bhabha National Institute, Mumbai, India
| |
Collapse
|
41
|
Perez M, Chakraborty A, Lau LS, Mohammed NBB, Dimitroff CJ. Melanoma-associated glycosyltransferase GCNT2 as an emerging biomarker and therapeutic target. Br J Dermatol 2021; 185:294-301. [PMID: 33660254 DOI: 10.1111/bjd.19891] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/20/2021] [Indexed: 12/17/2022]
Abstract
In metastatic melanoma, with a dismal survival rate and propensity for treatment resistance and recurrence, it is critical to establish biomarkers that better predict treatment response and disease severity. The melanoma glycome, composed of complex carbohydrates termed glycans, is an under-investigated area of research, although it is gaining momentum in the cancer biomarker and therapeutics field. Novel findings suggest that glycans play a major role in influencing melanoma progression and could be exploited for prognosticating metastatic activity and/or as therapeutic targets. In this review, we discuss the role of aberrant glycosylation, particularly the specialized function of β1,6 N-acetylglucosaminyltransferase 2 (GCNT2), in melanoma pathogenesis and summarize mechanisms of GCNT2 regulation to illuminate its potential as a predictive marker and therapeutic target.
Collapse
Affiliation(s)
- M Perez
- Department of Translational Medicine, Translational Glycobiology Institute at FIU, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA
| | - A Chakraborty
- Department of Translational Medicine, Translational Glycobiology Institute at FIU, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA
| | - L S Lau
- Department of Translational Medicine, Translational Glycobiology Institute at FIU, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA
| | - N B B Mohammed
- Department of Translational Medicine, Translational Glycobiology Institute at FIU, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA
| | - C J Dimitroff
- Department of Translational Medicine, Translational Glycobiology Institute at FIU, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA
| |
Collapse
|
42
|
Mitra A, Chakraborty A, Upadhye T, Verma P, Rajesh C, Lad S, Pawar Y, Basu S, Banerjee S. Clinical efficacy of Sep-Pak® assisted one pot automated synthesis of pharmaceutical grade [18F]FLT using 5′-O-(benzoyl)-2,3′-anhydrothymidine precursor. J Radioanal Nucl Chem 2021. [DOI: 10.1007/s10967-020-07531-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
43
|
Pandey V, Haider T, Chandak AR, Chakraborty A, Banerjee S, Soni V. Surface modified silk fibroin nanoparticles for improved delivery of doxorubicin: Development, characterization, in-vitro studies. Int J Biol Macromol 2020; 164:2018-2027. [PMID: 32758604 DOI: 10.1016/j.ijbiomac.2020.07.326] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2020] [Revised: 07/29/2020] [Accepted: 07/31/2020] [Indexed: 12/20/2022]
Abstract
Silk fibroin nanoparticles possess the hydrophobic nature which assists them to become a good substrate for reticulo-endothelial system (RES) and macrophageal uptake. Surface coating of these nanoparticles with hydrophilic stabilizers, like Tween-80 make them long circulating and facilitate their uptake by low density lipoprotein (LDL) receptors to cross blood brain barrier (BBB). Surface modified silk fibroin nanoparticles bearing anti-cancer agent doxorubicin (DOX) were fabricated by desolvation method and coated with Tween-80 as surface modifier. The prepared nanoparticles were characterized for various physicochemical parameters, like particle size, surface charge, surface morphology by scanning electron microscope (SEM) and transmission electron microscopy (TEM), and in vitro drug release along with in vitro cell cytotoxicity, flow cytometry and cellular uptake studies by flourocytometry on glioblastoma cell lines. Entrapment efficiency for the silk fibroin nanoparticles were found to be >85% for coated and uncoated nanoparticles. Nanoparticles with average diameter less than 150 nm having negative charge were found to show no toxicity of its own. The pro-inflammatory response of nanoparticles was observed by determining the cytokines level, such as TNF-α and IL-1β. Sustained drug release pattern from the nanoparticles with better cytotoxicty as compared to free drug was observed, signifying their potential ability to work as a drug delivery system.
Collapse
Affiliation(s)
- Vikas Pandey
- Department of Pharmaceutical Sciences, Dr. Harisingh Gour University, Sagar 470003, India
| | - Tanweer Haider
- Department of Pharmaceutical Sciences, Dr. Harisingh Gour University, Sagar 470003, India
| | - Ashok R Chandak
- Radiation Medicine Centre, Bhabha Atomic Research Centre (BARC), Mumbai 400012, India
| | - Avik Chakraborty
- Radiation Medicine Centre, Bhabha Atomic Research Centre (BARC), Mumbai 400012, India
| | - Sharmila Banerjee
- Radiation Medicine Centre, Bhabha Atomic Research Centre (BARC), Mumbai 400012, India
| | - Vandana Soni
- Department of Pharmaceutical Sciences, Dr. Harisingh Gour University, Sagar 470003, India.
| |
Collapse
|
44
|
Lameijer B, Antony J, Chakraborty A, Does R, Garza-Reyes J. The role of organisational motivation and coordination in continuous improvement implementations: an empirical research of process improvement project success. Total Quality Management & Business Excellence 2020. [DOI: 10.1080/14783363.2020.1757422] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Affiliation(s)
- B.A. Lameijer
- Department of Operations Management, University of Amsterdam, Amsterdam, The Netherlands
| | - J. Antony
- Department of Business Management, Heriot Watt University, Edinburgh, Scotland
| | - A. Chakraborty
- Department of Operations Management & Quantitative Techniques, Indian Institute of Management Tiruchirappalli, Trichy, India
| | - R.J.M.M. Does
- Department of Operations Management, University of Amsterdam, Amsterdam, The Netherlands
| | - J.A. Garza-Reyes
- Centre for Supply Chain Improvement, University of Derby, Derby, England
| |
Collapse
|
45
|
Pandey V, Haider T, Chandak AR, Chakraborty A, Banerjee S, Soni V. Technetium labeled doxorubicin loaded silk fibroin nanoparticles: Optimization, characterization and in vitro evaluation. J Drug Deliv Sci Technol 2020. [DOI: 10.1016/j.jddst.2020.101539] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
|
46
|
Singla R, Raghu B, Gupta A, Caminero JA, Sethi P, Tayal D, Chakraborty A, Jain Y, Migliori GB. Risk factors for early mortality in patients with pulmonary tuberculosis admitted to the emergency room. Pulmonology 2020; 27:35-42. [PMID: 32127307 DOI: 10.1016/j.pulmoe.2020.02.002] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2019] [Revised: 01/24/2020] [Accepted: 02/06/2020] [Indexed: 11/28/2022] Open
Abstract
BACKGROUND AND OBJECTIVES Mortality of patients with pulmonary tuberculosis (TB) admitted to emergency departments is high. This study was aimed at analysing the risk factors associated with early mortality and designing a risk score based on simple parameters. METHODS This prospective case-control study enrolled patients admitted to the emergency department of a referral TB hospital. Clinical, radiological, biochemical and microbiological risk factors associated with death were compared among patients dying within one week from admission (cases) and those surviving (controls). RESULTS Forty-nine of 250 patients (19.6%) experienced early mortality. Multiple logistic regression analysis showed that oxygen saturation (SaO2) ≤90%, severe malnutrition, tachypnoea, tachycardia, hypotension, advanced disease at chest radiography, severe anaemia, hyponatremia, hypoproteinemia and hypercapnia were independently and significantly associated with early mortality. A clinical scoring system was further designed to stratify the risk of death by selecting five simple parameters (SpO2 ≤ 90%, tachypnoea, hypotension, advanced disease at chest radiography and tachycardia). This model predicted early mortality with a positive predictive value of 94.88% and a negative predictive value of 19.90%. CONCLUSIONS The scoring system based on simple parameters may help to refer severely ill patients early to a higher level to reduce mortality, improve success rates, minimise the need for pulmonary rehabilitation and prevent post-treatment sequelae.
Collapse
Affiliation(s)
- R Singla
- Department of Tuberculosis and Chest Diseases, National Institute of Tuberculosis and Respiratory Diseases, New Delhi, 110030, India.
| | - B Raghu
- Department of Tuberculosis and Chest Diseases, National Institute of Tuberculosis and Respiratory Diseases, New Delhi, 110030, India
| | - A Gupta
- Department of Tuberculosis and Chest Diseases, National Institute of Tuberculosis and Respiratory Diseases, New Delhi, 110030, India
| | - J A Caminero
- Pneumology Department, Hospital General de Gran Canaria "Dr. Negrin", Las Palmas de Gran Canaria, 35010, Spain; MDR-TB Unit, Tuberculosis Division, International Union against Tuberculosis and Lung Disease, Paris 75006, France
| | - P Sethi
- Department of Tuberculosis and Chest Diseases, National Institute of Tuberculosis and Respiratory Diseases, New Delhi, 110030, India
| | - D Tayal
- Department of Biochemistry, National Institute of Tuberculosis and Respiratory Diseases, New Delhi 110030, India
| | - A Chakraborty
- Department of Tuberculosis and Chest Diseases, National Institute of Tuberculosis and Respiratory Diseases, New Delhi, 110030, India
| | - Y Jain
- Jan Swasthya Sahyog, Bilaspur, Ganiyari, Chhattisgarh 495112, India
| | - G B Migliori
- Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri IRCCS, Tradate, 21049, Italy; Blizard Institute, Queen Mary University of London, 4 Newark St, Whitechapel, London E1 2AT, United Kingdom
| |
Collapse
|
47
|
Padhy SR, Bhattacharyya P, Dash PK, Reddy CS, Chakraborty A, Pathak H. Seasonal fluctuation in three mode of greenhouse gases emission in relation to soil labile carbon pools in degraded mangrove, Sundarban, India. Sci Total Environ 2020; 705:135909. [PMID: 31839306 DOI: 10.1016/j.scitotenv.2019.135909] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/02/2019] [Revised: 11/27/2019] [Accepted: 12/01/2019] [Indexed: 06/10/2023]
Abstract
Tropical mangrove represents one of the most threatened ecosystems despite their huge contribution to ecosystem services, carbon (C) sequestration and climate change mitigation. Understanding the system in light of seasonal fluctuations on greenhouse gases (GHGs) emissions due to human interferences and the tidal effect is important for devising site-specific real-time climate change mitigation strategies. In order to capture the seasonal variations, the three modes of transport of GHGs through pneumatophore, ebullition as bubbles and water-soluble diffusion was quantified. The three unique techniques for the gas collection were used to estimate the GHGs [methane (CH4), nitrous oxide (N2O) and carbon dioxide (CO2)] emission, at three degraded-mangrove sites in Sundarban, India. We identified three degraded mangrove ecologies based on the remote sensing data of 1930 and 2013 (mangrove-covered area in Sundarban; 2387, 2136 km2, respectively). Samples were collected and analyzed for four seasons [winter (November-January), summer (February-April), pre-monsoon (May-June) and monsoon (July-October)], at three representative sites (Sadhupur, Dayapur, and Pakhiralaya). Monsoonal CH4 and CO2 fluxes (0.353 ± 0.026 and 64.5 ± 6.1 mmol m-2 d-1, respectively) were higher than winter and summer. However, the soil labile C pools showed the opposite trend i.e. more in summer followed by winter and monsoon. In contrast, the N2O fluxes were more during summer (54.2 ± 3.2 μmol m-2 d-1). The stagnant water had higher dissolved GHGs concentration compared to tidewater due to less salinity and a long time of stagnation. The mode of transport of GHGs through pneumatophore, ebullition, and water-soluble diffusion was also significantly varied with seasons, soil‑carbon status and tidewater intrusion. Therefore, seasonal fluctuations of GHGs emission and tidal effect must be considered along with soil labile C pools for GHG-C budgeting and climate change mitigation in the mangrove ecosystem.
Collapse
Affiliation(s)
- S R Padhy
- ICAR-National Rice Research Institute (NRRI), Cuttack, Odisha, India
| | - P Bhattacharyya
- ICAR-National Rice Research Institute (NRRI), Cuttack, Odisha, India.
| | - P K Dash
- ICAR-National Rice Research Institute (NRRI), Cuttack, Odisha, India
| | - C S Reddy
- National Remote Sensing Centre, Hyderabad, India
| | | | - H Pathak
- ICAR-National Rice Research Institute (NRRI), Cuttack, Odisha, India
| |
Collapse
|
48
|
Rahman M, Chakraborty A, Mazumdar S, Nandi N, Bhuiyan M, Alauddin S, Khan I, Hossain MJ. Effects of poly(vinylpyrrolidone) protected platinum nanoparticles on seed germination and growth performance of Pisum sativum. ACTA ACUST UNITED AC 2020. [DOI: 10.1016/j.nanoso.2019.100408] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
49
|
Serianni G, Toigo V, Bigi M, Boldrin M, Chitarin G, Dal Bello S, Grando L, Luchetta A, Marcuzzi D, Pasqualotto R, Pomaro N, Zaccaria P, Zanotto L, Agostinetti P, Agostini M, Antoni V, Aprile D, Barbisan M, Battistella M, Brombin M, Canton A, Cavazzana R, Dalla Palma M, Dan M, Delogu R, De Lorenzi A, De Muri M, Denizeau S, Fadone M, Fellin F, Ferro A, Gaio E, Gambetta G, Gasparini F, Gnesotto F, Jain P, Maistrello A, Manduchi G, Manfrin S, Marchiori G, Marconato N, Moresco M, Patton T, Pavei M, Peruzzo S, Pilan N, Pimazzoni A, Piovan R, Poggi C, Recchia M, Rigoni A, Rizzolo A, Rostagni G, Sartori E, Siragusa M, Sonato P, Spada E, Spagnolo S, Spolaore M, Taliercio C, Tinti P, Ugoletti M, Valente M, Zamengo A, Zaniol B, Zaupa M, Cavenago M, Boilson D, Rotti C, Veltri P, Chareyre J, Decamps H, Dremel M, Graceffa J, Geli F, Schunke B, Svensson L, Urbani M, Bonicelli T, Agarici G, Garbuglia A, Masiello A, Paolucci F, Simon M, Bailly-Maitre L, Bragulat E, Gomez G, Gutierrez D, Labate C, Mico G, Moreno JF, Pilard V, Kouzmenko G, Rousseau A, Chakraborty A, Baruah U, Patel H, Singh NP, Patel A, Dhola H, Raval B, Cristofaro S, Fantz U, Heinemann B, Kraus W, Kashiwagi M, Tobari H. First operation in SPIDER and the path to complete MITICA. Rev Sci Instrum 2020; 91:023510. [PMID: 32113382 DOI: 10.1063/1.5133076] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/26/2019] [Accepted: 01/22/2020] [Indexed: 06/10/2023]
Abstract
The requirements of ITER neutral beam injectors (1 MeV, 40 A negative deuterium ion current for 1 h) have never been simultaneously attained; therefore, a dedicated Neutral Beam Test Facility (NBTF) was set up at Consorzio RFX (Padova, Italy). The NBTF includes two experiments: SPIDER (Source for the Production of Ions of Deuterium Extracted from Rf plasma), the full-scale prototype of the source of ITER injectors, with a 100 keV accelerator, to investigate and optimize the properties of the ion source; and MITICA, the full-scale prototype of the entire injector, devoted to the issues related to the accelerator, including voltage holding at low gas pressure. The present paper gives an account of the status of the procurements, of the timeline, and of the voltage holding tests and experiments for MITICA. As for SPIDER, the first year of operation is described, regarding the solution of some issues connected with the radiofrequency power, the source operation, and the characterization of the first negative ion beam.
Collapse
Affiliation(s)
- G Serianni
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - V Toigo
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - M Bigi
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - M Boldrin
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - G Chitarin
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - S Dal Bello
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - L Grando
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - A Luchetta
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - D Marcuzzi
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - R Pasqualotto
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - N Pomaro
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - P Zaccaria
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - L Zanotto
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - P Agostinetti
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - M Agostini
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - V Antoni
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - D Aprile
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - M Barbisan
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - M Battistella
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - M Brombin
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - A Canton
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - R Cavazzana
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - M Dalla Palma
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - M Dan
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - R Delogu
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - A De Lorenzi
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - M De Muri
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - S Denizeau
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - M Fadone
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - F Fellin
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - A Ferro
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - E Gaio
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - G Gambetta
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - F Gasparini
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - F Gnesotto
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - P Jain
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - A Maistrello
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - G Manduchi
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - S Manfrin
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - G Marchiori
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - N Marconato
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - M Moresco
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - T Patton
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - M Pavei
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - S Peruzzo
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - N Pilan
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - A Pimazzoni
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - R Piovan
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - C Poggi
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - M Recchia
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - A Rigoni
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - A Rizzolo
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - G Rostagni
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - E Sartori
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - M Siragusa
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - P Sonato
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - E Spada
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - S Spagnolo
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - M Spolaore
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - C Taliercio
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - P Tinti
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - M Ugoletti
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - M Valente
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - A Zamengo
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - B Zaniol
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - M Zaupa
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - M Cavenago
- INFN-Laboratori Nazionali di Legnaro (LNL), v.le dell'Università 2, I-35020 Legnaro, PD, Italy
| | - D Boilson
- ITER Organization, Route de Vinon-sur-Verdon, CS 90 046, F-13067 St. Paul-lez-Durance, France
| | - C Rotti
- ITER Organization, Route de Vinon-sur-Verdon, CS 90 046, F-13067 St. Paul-lez-Durance, France
| | - P Veltri
- ITER Organization, Route de Vinon-sur-Verdon, CS 90 046, F-13067 St. Paul-lez-Durance, France
| | - J Chareyre
- ITER Organization, Route de Vinon-sur-Verdon, CS 90 046, F-13067 St. Paul-lez-Durance, France
| | - H Decamps
- ITER Organization, Route de Vinon-sur-Verdon, CS 90 046, F-13067 St. Paul-lez-Durance, France
| | - M Dremel
- ITER Organization, Route de Vinon-sur-Verdon, CS 90 046, F-13067 St. Paul-lez-Durance, France
| | - J Graceffa
- ITER Organization, Route de Vinon-sur-Verdon, CS 90 046, F-13067 St. Paul-lez-Durance, France
| | - F Geli
- ITER Organization, Route de Vinon-sur-Verdon, CS 90 046, F-13067 St. Paul-lez-Durance, France
| | - B Schunke
- ITER Organization, Route de Vinon-sur-Verdon, CS 90 046, F-13067 St. Paul-lez-Durance, France
| | - L Svensson
- ITER Organization, Route de Vinon-sur-Verdon, CS 90 046, F-13067 St. Paul-lez-Durance, France
| | - M Urbani
- ITER Organization, Route de Vinon-sur-Verdon, CS 90 046, F-13067 St. Paul-lez-Durance, France
| | - T Bonicelli
- Fusion for Energy, C/o Josep Pla 2, E-08019 Barcelona, Spain
| | - G Agarici
- Fusion for Energy, C/o Josep Pla 2, E-08019 Barcelona, Spain
| | - A Garbuglia
- Fusion for Energy, C/o Josep Pla 2, E-08019 Barcelona, Spain
| | - A Masiello
- Fusion for Energy, C/o Josep Pla 2, E-08019 Barcelona, Spain
| | - F Paolucci
- Fusion for Energy, C/o Josep Pla 2, E-08019 Barcelona, Spain
| | - M Simon
- Fusion for Energy, C/o Josep Pla 2, E-08019 Barcelona, Spain
| | - L Bailly-Maitre
- Fusion for Energy, C/o Josep Pla 2, E-08019 Barcelona, Spain
| | - E Bragulat
- Fusion for Energy, C/o Josep Pla 2, E-08019 Barcelona, Spain
| | - G Gomez
- Fusion for Energy, C/o Josep Pla 2, E-08019 Barcelona, Spain
| | - D Gutierrez
- Fusion for Energy, C/o Josep Pla 2, E-08019 Barcelona, Spain
| | - C Labate
- Fusion for Energy, C/o Josep Pla 2, E-08019 Barcelona, Spain
| | - G Mico
- Fusion for Energy, C/o Josep Pla 2, E-08019 Barcelona, Spain
| | - J F Moreno
- Fusion for Energy, C/o Josep Pla 2, E-08019 Barcelona, Spain
| | - V Pilard
- Fusion for Energy, C/o Josep Pla 2, E-08019 Barcelona, Spain
| | - G Kouzmenko
- Fusion for Energy, C/o Josep Pla 2, E-08019 Barcelona, Spain
| | - A Rousseau
- Fusion for Energy, C/o Josep Pla 2, E-08019 Barcelona, Spain
| | - A Chakraborty
- ITER-India, Institute for Plasma Research, Nr. Indira Bridge, Bhat Village, Gandhinagar, Gujarat 382428, India
| | - U Baruah
- ITER-India, Institute for Plasma Research, Nr. Indira Bridge, Bhat Village, Gandhinagar, Gujarat 382428, India
| | - H Patel
- ITER-India, Institute for Plasma Research, Nr. Indira Bridge, Bhat Village, Gandhinagar, Gujarat 382428, India
| | - N P Singh
- ITER-India, Institute for Plasma Research, Nr. Indira Bridge, Bhat Village, Gandhinagar, Gujarat 382428, India
| | - A Patel
- ITER-India, Institute for Plasma Research, Nr. Indira Bridge, Bhat Village, Gandhinagar, Gujarat 382428, India
| | - H Dhola
- ITER-India, Institute for Plasma Research, Nr. Indira Bridge, Bhat Village, Gandhinagar, Gujarat 382428, India
| | - B Raval
- ITER-India, Institute for Plasma Research, Nr. Indira Bridge, Bhat Village, Gandhinagar, Gujarat 382428, India
| | - S Cristofaro
- IPP, Max-Planck-Institut für Plasmaphysik, Boltzmannstraße 2, D-85748 Garching bei München, Germany
| | - U Fantz
- IPP, Max-Planck-Institut für Plasmaphysik, Boltzmannstraße 2, D-85748 Garching bei München, Germany
| | - B Heinemann
- IPP, Max-Planck-Institut für Plasmaphysik, Boltzmannstraße 2, D-85748 Garching bei München, Germany
| | - W Kraus
- IPP, Max-Planck-Institut für Plasmaphysik, Boltzmannstraße 2, D-85748 Garching bei München, Germany
| | - M Kashiwagi
- National Institutes for Quantum and Radiological Science and Technology, 801-1 Mukoyama, Naka, Ibaraki-ken 311-0193, Japan
| | - H Tobari
- National Institutes for Quantum and Radiological Science and Technology, 801-1 Mukoyama, Naka, Ibaraki-ken 311-0193, Japan
| |
Collapse
|
50
|
Chandrasekhar V, Chakraborty A. Status of Inorganic Chemistry Research in India. PINSA 2019. [DOI: 10.16943/ptinsa/2019/49735] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|